

Edgar Filing: Healthsport, Inc. - Form 10-K

Healthsport, Inc.
Form 10-K
April 15, 2008

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-K

ANNUAL REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

FOR THE FISCAL YEAR ENDED DECEMBER 31, 2007

COMMISSION FILE NUMBER 0-23100

HEALTHSPORT, INC.
(Exact name of small business issuer in its charter)

DELAWARE
(State or Other Jurisdiction
of Incorporation or Organization)

22-2649848
(IRS Employer
Identification No.)

7633 E 63RD PLACE, SUITE 220, TULSA, OK
(Address of Principal Executive Office)

74133
(Zip Code)

ISSUER'S TELEPHONE NUMBER (716) 691-6763

SECURITIES REGISTERED UNDER SECTION 12(b) OF THE EXCHANGE ACT: NONE

SECURITIES REGISTERED UNDER SECTION 12(g) OF THE EXCHANGE ACT:

COMMON STOCK, \$0.0001 PAR VALUE
(TITLE OF EACH CLASS)

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act Yes []; No [X].

Indicate by check mark whether the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Exchange Act. Yes []; No [X].

Indicate by check mark if the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes? [X]; No []. Indicate by check mark if disclosure of delinquent filers in response to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of registrant's knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K [].

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definition of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer [] Accelerated filer []
Non-accelerated filer [] Smaller reporting company [X]

(Do not check if a smaller reporting company)

Indicate by check mark whether the registrant is a shell company (as defined in rule 12b-2 of the Exchange Act). Yes []; No [X]. State the aggregate market

Edgar Filing: Healthsport, Inc. - Form 10-K

value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and ask price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter. \$41,252,289.

As of February 29, 2008, the registrant had outstanding 42,898,397 shares of its common stock, par value of \$0.0001, its only class of voting securities.

DOCUMENTS INCORPORATED BY REFERENCE

No documents are incorporated by reference into this Report except those Exhibits so incorporated as set forth in the Exhibit index.

HEALTHSPORT, INC.

TABLE OF CONTENTS

FORM 10-K

Part I

		Page
PART I		
Item 1	Business	3
Item 1A	Risk Factors	11
Item 2	Properties	11
Item 3	Legal Proceedings	12
Item 4	Submission of Matters to a Vote of Security Holders	12
PART II		
Item 5	Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities	13
Item 6	Selected Financial Data	15
Item 7	Management's Discussion and Analysis of Financial Condition and Results of Operation	15
Item 7A	Quantitative and Qualitative Disclosures about Market Risk	20
Item 8	Financial Statements and Supplementary Data	21
Item 9	Changes in and Disagreements with Accountants on Accounting and Financial Disclosure	47
Item 9A(T)	Controls and Procedures	47
Item 9B	Other Information	48
PART III		
Item 10	Directors, Executive Officers and Corporate Governance	49
Item 11	Executive Compensation	52
Item 12	Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters	56
Item 13	Certain Relationships and Related Transactions, and Director Independence	58
Item 14	Principal Accountant Fees and Services	59
PART IV		
Item 15	Exhibits and Financial Statement Schedules	60

From time to time, we may publish forward-looking statements relative to such matters as anticipated financial results, business prospects, technological

Edgar Filing: Healthsport, Inc. - Form 10-K

developments and similar matters. The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements. The following discussion and analysis should be read in conjunction with the report on the Consolidated Financial Statements and the accompanying Notes to Consolidated Financial Statements appearing later in this report. All statements other than statements of historical fact included in this Annual Report on Form 10-K are, or may be deemed to be, forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Exchange Act of 1934, as amended. Important factors that could cause actual results to differ materially from those discussed in such forward-looking statements include, but are not limited to, the following: our current liquidity needs, as described in our periodic reports; changes in the economy; our inability to raise additional capital; our involvement in potential litigation; volatility of our stock price; the variability and timing of business opportunities; changes in accounting policies and practices; the effect of internal organizational changes; adverse state and federal regulation and legislation; and the occurrence of extraordinary or catastrophic events and terrorist acts. These factors and others involve certain risks and uncertainties that could cause actual results or events to differ materially from management's views and expectations. Inclusion of any information or statement in this report does not necessarily imply that such information or statement is material. We do not undertake any obligation to release publicly revised or updated forward-looking information, and such information included in this report is based on information currently available and may not be reliable after this date.

PART I

ITEM 1: BUSINESS

BUSINESS DEVELOPMENT

HealthSport, Inc. (together with its subsidiaries, hereinafter referred to as the "Company", "HealthSport", "we" or "us"), is a holding company, originally incorporated on July 25, 1985 in Delaware, and currently has the following wholly owned subsidiaries:

- o Enlyten, Inc. ("Enlyten"), a Nevada corporation organized on November 28, 2006;
- o Health Strip Solutions, LLC ("Health Strip"), a Nevada limited liability corporation organized on February 13, 2006; acquired 80% on March 29, 2006, 10% on December 21, 2006 and the remaining 10% on December 27, 2006;
- o Cooley Nutraceuticals, Inc. ("Nutraceuticals"), a Nevada corporation organized on November 17, 2006; acquired on December 6, 2006;
- o InnoZen, Inc. ("InnoZen"), a Nevada corporation organized on May 30, 2002; acquired on May 4, 2007;
- o Maxx Motorsports, Inc. ("Maxx"), a Delaware corporation acquired on May 15, 2001 and currently inactive;
- o World Championship Poker, Inc. ("Poker"), a Nevada corporation acquired on June 28, 2005 and currently inactive; and
- o Strategic Gaming Consultants, LLC, ("Gaming"), a Nevada limited liability corporation organized on November 8, 2004, and never activated.

On April 24, 2006, we filed a Definitive Information Statement pursuant to Section 14C which provided that effective May 15, 2006; 1) our name would be changed to HealthSport, Inc.; 2) our issued and outstanding shares would be reverse-split one share for each 200 shares; and 3) our Certificate of

Edgar Filing: Healthsport, Inc. - Form 10-K

Incorporation would be restated to reflect these amendments. These amendments were approved by our Board of Directors and in writing by 52.33% of our shareholders on March 31, 2006. Accordingly, effective May 15, 2006, our name was changed to HealthSport, Inc., our shares were reverse-split one for 200 and our Certificate of Incorporation was restated to reflect these amendments. We have made the change in outstanding shares and all references to shares have been retroactively restated for all periods included in this report on Form 10-K.

HealthSport, Inc. was originally incorporated in 1985 as Horizon Capital Corp. We were known as Reconversion Technologies, Inc. until May 1, 2000, at which time our name was changed to Logisoft Corp. On May 15, 2001, we changed our name from Logisoft Corp. to Team Sports Entertainment, Inc., on November 8, 2004, we changed our name to Idea Sports Entertainment Group, Inc. and on May 15, 2006, we changed our name to HealthSport, Inc.

INNOZEN ACQUISITION

On May 4, 2007, the Company completed the acquisition of InnoZen through a merger of InnoZen with InnoZen Acquisition Sub, Inc. ("Acquisition Sub"), the Company's wholly owned subsidiary, all Delaware corporations, in exchange for 18,249,952 shares of the Company's common stock. In accordance with Delaware General Corporate Law and pursuant to the terms and conditions of the Merger Agreement, Acquisition Sub was merged with and into InnoZen, after which, InnoZen became the Company's wholly owned subsidiary and continues as the surviving corporation and the separate existence of Acquisition Sub ceased.

InnoZen is the preeminent formulator, developer and manufacturer of edible thin film strips that deliver drug actives and was the first company to deliver a drug active ingredient in a thin film strip when it completed the development of Chloraseptic(R) Sore Throat Relief Strips in June 2003. With Chloraseptic Relief Strips, InnoZen established a new process which prevented irritants and incorporated additional compounds to make the strips more suitable for various drug delivery needs. Relying on its expertise in the development of edible film strips that deliver drug actives, InnoZen moved forward with its proprietary technology to develop two new thin film strip products for cough. InnoZen launched its two new film strip products under its own Suppress(R) brand (<http://www.suppress.com>) in September 2004.

The acquisition was accounted for using the purchase method of accounting and, accordingly, the consolidated statements of operations include the results of InnoZen beginning May 4, 2007. The assets acquired and the liabilities assumed were recorded at estimated fair values as determined by the Company's management based on information currently available and on current assumptions as to future operations.

BUSINESS OF THE COMPANY

HealthSport is publicly traded on the bulletin board market under the ticker symbol HSPO.OB. HealthSport is focused exclusively on the development, manufacturing, distribution and marketing of edible film strip products containing nutritional supplements and over-the-counter drugs using certain proprietary technology. This technology system provides rapid dissolution and release of active ingredients when the strip comes in contact with saliva in the mouth.

InnoZen was the first company to deliver a drug in an edible film strip and maintains proprietary edible film strip technology pertaining to method of manufacture, including administration of drug and nutritional supplements via

Edgar Filing: Healthsport, Inc. - Form 10-K

its unique bi-layer process. InnoZen has pending patents relating to use and administration of Transmucosal delivery of nutritional supplements and the Patent Cooperation Treaty suggests that we will maintain world-wide novelty of all patents. InnoZen maintains additional trade secrets of product and flavor formulation and manufacture of its film strip products.

Using InnoZen's in-house research, development and manufacturing capabilities, HealthSport has the ability to rapidly formulate and develop new thin film products and other products using various additional oral delivery systems such as gels. As a result, HealthSport anticipates a steady stream of new products to expand the Enlyten brand it is creating. The implementation of HealthSport's sales and marketing models for each product line will play an integral role in creating brand awareness through the application of traditional and non-traditional sales techniques.

In 2008, InnoZen entered into a joint venture agreement with Migami, Inc. and is 52% owner of Pacific Manufacturing Group, LLC ("PMG"), which was formed to build a world-wide regulatory compliant manufacturing facility with cutting edge innovation and stringent quality control, which will be cGMP compliant. Current manufacturing is completed at the InnoZen laboratory and pilot plant in Woodland Hills, California. The new facility is located in Ventura, California and is scheduled for completion in the summer of 2008.

Enlyten was formed to develop, brand, secure domestic and international distribution, launch and market our various product lines through the execution of targeted and strategic marketing plans.

HealthSport and InnoZen have already jointly developed three new products that launched in 2007, including ENLYTEN(TM) SPORTSTRIPS, ENLYTEN(TM) PEDIASSTRIPS and FIX STRIPS.

From September 9, 2004 until it was sold to a former CEO of the Company in 2006, the Company operated primarily through Idea Management Group, Inc., a concept development company that internally created projects in the fields of professional sports, motion pictures, publishing, licensed merchandise and other entertainment products.

From May 15, 2001, until operations were discontinued on August 26, 2003, the Company operated through its wholly owned subsidiary Maxx and its wholly owned subsidiary TRAC with plans to develop, own, operate and sanction an automotive racing league designed to provide content for television and tracks.

5

PRODUCT OVERVIEW

Our mission is to be a leader in developing and manufacturing pharmaceutical products in unique and convenient oral delivery formats using science and innovation to improve people's lives. The main method of achieving this is by use of "medicine in a strip"(R) that can be orally ingested. Flavor is an important part of the film strip development process and our team has extensive experience in developing flavors in film strips and has great relationships with numerous international flavor houses.

This goal can be achieved by creatively applying our unique, proprietary knowledge and technology to create unique medicines in a strip that enable drug developers to have an alternative and proprietary method of delivering their existing products, as well as new products, and of extending and expanding their respective market positions, brands, distribution networks and intellectual property.

Edgar Filing: Healthsport, Inc. - Form 10-K

ENLYTEN(TM) SPORTSTRIPS

Over the past year and half, InnoZen has been applying its film strip technology formulation and manufacturing expertise to develop film strips containing electrolytes. Electrolytes are chemicals that form electrically-charged particles (ions) in body fluids. These ions carry the electrical energy necessary for many functions, including nerve impulse transmission and muscle contractions.

Many normal body functions depend on electrolytes, and optimal athletic performance requires a consistent and adequate supply of these important nutrients. Electrolytes such as those found in ENLYTEN(TM) SPORTSTRIPS, along with water, can be used in oral rehydration therapy to replenish the body's electrolyte levels after dehydration caused by exercise, diarrhea or vomiting. Drinking water alone is not the best way to restore fluid levels after extreme athletic activity because it dilutes the salts inside the body's cells and interferes with their chemical functions. This can lead to water intoxication. (This and other side-effects can be a similar negative consequence of excess ingestion of popular liquid electrolyte solutions.)

Our ENLYTEN(TM) SPORT STRIPS have been tested by Dr. David Berkoff of Duke Sports Medicine's K-Lab and have so far provided positive results. With the patented film strip technology developed by InnoZen and testing completed by Dr. Berkoff, we began marketing ENLYTEN(TM) SPORTSTRIPS in the summer of 2007.

ENLYTEN(TM) PEDIASTRIPS

We have developed a new product customized to replenish electrolytes and aid in faster and more efficient hydration for children with flue symptoms, vomiting or diarrhea. ENLYTEN(TM) PEDIASTRIPS are a cutting edge technology that delivers essential electrolytes To children without sugar or other non-essential additives. We began marketing PediaStrips in the fourth quarter of 2007.

FIX STRIPS(TM)

FIX STRIPS were developed to provide fast, effective and safe relief for those individuals who incorporate social drinking into their lifestyle. FIX STRIPS are a nutritional supplement that quickly and effectively provides caffeine, electrolytes, antioxidants and other essential vitamins and minerals. We began marketing FIX STRIPS in the fourth quarter of 2007.

6

ENLYTEN(TM) ENERGY FILM STRIPS

We have developed a revolutionary new edible film strip. ENLYTEN(TM) ENERGY film strips are a nutritional supplement that quickly and effectively provides natural energy enhancers, caffeine, electrolytes, antioxidants, and other essential vitamins and minerals. Our proprietary formulation is designed to supply the body with a healthy boost in energy, while replenishing and maintaining the essential vitamins and minerals lost during activity, after a long flight, bad night of sleep or over indulgence of alcohol. We expect to begin marketing ENLYTEN(TM) ENERGY film strips during the summer of 2008.

ENLYTEN(TM) SURVIVAL STRIPS

Edgar Filing: Healthsport, Inc. - Form 10-K

We are currently working with the United States Military to evaluate and test the effectiveness of ENLYTEN(TM) SURVIVAL STRIPS. ENLYTEN(TM) SURVIVAL STRIPS are formulated with antioxidants, non-cavity causing sweeteners, vitamins, herbal extracts, electrolytes, caffeine and other proven beneficial compounds. ENLYTEN(TM) SURVIVAL STRIPS were designed specifically for military personnel as a convenient, light weight, heat stable, effective remedy to fatigue, drowsiness, dehydration and loss of performance during routine and special operations. The strips are being examined in military populations to evaluate their effectiveness in providing energy, increasing alertness, combating dehydration and improving performance in extended operations.

SUPPRESS STRIPS(R)

InnoZen launched Suppress Cough Strips in 2004 to treat coughs, colds and sore throats. Suppress Cough Strips are available in two formulations: one with Dextromethorphan, and one in an herbal formulation. Both are available for purchase in approximately 10,000 retail outlets in the U.S. The product is carried in numerous leading chain stores such as Rite Aid, Winn Dixie, Drugstore.com, Eckerd, Ralph's and Longs Drugs. InnoZen has also arranged for international distribution of these products.

CHLORASEPTIC STRIPS

Less than one year after incorporating, InnoZen completed formulation and development of its first film strip product, a Benzocaine film strip, and licensed it to Prestige Brands to launch under Prestige's Chloraseptic(R) brand in 2003. The Chloraseptic Sore Throat Relief Strips developed by InnoZen were the first thin film strip containing a drug active and are currently being marketed in the U.S. InnoZen currently receives a royalty for Chloraseptic's use of its licensed technology.

PRODUCTS UNDER DEVELOPMENT

We are currently working on a number of additional products which can be delivered using our bi-layer strip delivery. These include pain relievers, anti-diarrhea, weight-loss, sedatives, vitamin and anti-oxidant products, as well as, animal vitamins and supplements.

7

INDUSTRY OVERVIEW

Oral film strips supplement and can replace traditional capsules and tablets due to their ease of use, discreteness, portability, fast oral delivery, and ability to control dosage (and thus minimize overdosing and/or contraindications of the active ingredients). Film strips have soothing effects in the mouth and throat because of their method of dissolution. The success of Listerine(R) Breath Strips, which achieved more than \$500 million in sales since its launch, has demonstrated consumer acceptance and adoption of this new delivery system. Edible film strips have become a popular alternative to lozenges and gum for refreshing breath.

The film strip industry is in its early growth stage and we are currently one of the premier strip manufacturers in the country and have current and prospective substantial market presence and alliances in place. Additional products under development provide us with further upside opportunity.

SALES & DISTRIBUTION

Edgar Filing: Healthsport, Inc. - Form 10-K

To handle all of the sales, marketing, and distribution needs of our various products, we have formed Enlyten as a wholly owned subsidiary. Led by Dan Kelly, Enlyten began marketing and distributing the film strips using all forms of traditional outlets including grocery and drug stores, big box retailers and sporting goods stores. We will also utilize non-traditional avenues such as college bookstores, organizational events and nightclubs.

To further this effort, we have secured the services of a 28 year veteran in sales, Gary Thomas, who will be guiding and directing the Sales Division. His experience with Acosta, the largest food and medicine broker in the U.S., will bring substantial expertise and experience in the sales and distribution of our products. Under Mr. Thomas's supervision, Acosta's North Eastern United States Division recorded \$200+ million in annual sales revenue.

On March 11, 2008, we completed a five-year distribution deal with Unico Holdings, Inc. ("Unico"). Unico markets its products through numerous sales channels, including large retail merchandisers, drug store chains, grocery stores and pharmaceutical distributors. Unico's customers include most of the largest retailers and distributors in the U.S. in each of these sales channels. The agreement calls for a minimum of \$22 million of product purchases over the five-year term in order for Unico to maintain its exclusive distribution right.

PRODUCT POSITIONING & MARKETING

CLINICAL EXPERTS: The research and development conducted by Dr. David Berkoff and Anthony Seaber, medical doctors and experts in sports medicine at Duke University, and by other clinical experts on the ENLYTEN products will be communicated to other medical experts, coaches and trainers in each field along with the benefits the products have to offer, not only to professional athletes but to individuals as well. Their participation is important to reinforce the scientific verification data by offering their assessments and results with trainers, coaches, athletes, military personnel and the general public. The clinical experts are incorporated into our marketing plans through public relations and product testimonials in medical related materials circulated at trade shows, in medical magazines and on talk shows.

8

TRADESHOWS / CONFERENCES / EVENTS: Various tradeshows, conferences and opportunities exist where ENLYTEN(TM) SPORTSTRIPS, ENLYTEN(TM) PEDIASTRIPS, FIX STRIPS, ENLYTEN(TM) ENERGY film strips and ENLYTEN(TM) SURVIVAL STRIPS, as well as Suppress and our other products, can be introduced to the general public and to health, fitness, and sports professionals. In fact, it will be important to identify the events that will offer maximum exposure to achieve success and results of the investment to participate in the event, tradeshow or conference.

The marketing department will determine the high visibility tradeshows or events and oversee the logistics. The products will be sampled by direct placement in the hands of attendees at the events, through public relations surrounding the event and by using the endorsement of individuals at the events.

ADVERTISING: A multi-tiered program will be developed and executed to introduce each product to the general public, sports professionals and military. Each product will have a program and advertising schedule that will use new and established avenues for product placement, targeted media outlets in print and radio as well as using the Internet for education and direct sales.

Marketing and creative services will identify the target markets and publications to promote our products through advertisements and product story placements. High profile, nationally circulated newspapers, magazines and

Edgar Filing: Healthsport, Inc. - Form 10-K

product specific publications will be included in the print ad placement schedule, such as (but not limited to) USA TODAY, NEWSWEEK, RUNNER'S WORLD and other publications.

Direct mail will be sent out to conference participants, event sponsors and tradeshow mailing lists. The marketing department will work with the Sports Advisory Council and clinical experts to secure lists of contacts from them to mail materials to individuals and businesses in their circle of influence.

Consumers and retail customers will be mailed information and products, based on researched buying habits in specific markets and retail stores. The direct mail program will support promotional programs, consumer rebate initiatives and other opportunities coinciding with the retail-marketing plan for our brands.

Website advertising opportunities will be researched and developed to place advertising on highly visible Internet sites to extend the branding of HealthSport beyond print and direct mail.

Other developments will be specific to the needs of the product rollout, sales department and direction as given by our corporate executives.

PUBLIC RELATIONS: An integrated public relations program will be developed to launch us across the country as well as internationally. Working with a public relations agency, the customary elements will be created such as press releases, targeted pitch strategies and materials to be sent to the public.

At the conferences or tradeshows, members of the Sports Advisory Council may participate as presenters or attend the conferences. Local media market opportunities will be utilized for on and off-site interviews and related opportunities that will capitalize on the visibility of the conferences or tradeshows.

9

Additional product placement opportunities will be sought on content specific television shows, both locally and nationally, to provide support to marketing and sales related plans as determined by our corporate leadership.

MANUFACTURING

InnoZen maintains a drug research and development facility and a manufacturing plant in Woodland Hills, California that meets FDA and California certification requirements. This manufacturing facility provides new business opportunities through customized product production and pilot scale runs of film strip products, and the ability to then deliver final product quickly and at reasonable cost. Internal manufacturing enables quicker and more responsive development of new and custom formulations and provides the ability to then promptly fill orders for the new products. The net result is our unique ability to develop and deliver new film strip formulations and products to market faster and more economically.

CUSTOM CUTTING AND PACKAGING: Our cutting and packaging facility can be optimized to meet the specific requirements, and budgets, of our clients. Using high-tech labeling equipment, we offer a range of labeling options, including a tamper resistant seal and full wrap-around application. Technologically advanced blister card machinery enables us to offer retail ready packaging, blister card single and multi-packs and flow-wrap individual products. We also offer a number of innovative packaging solutions, including space saving packaging designs.

CAPACITY AND INVENTORY MANAGEMENT: With its own on-site manufacturing strip facility, InnoZen is in position to manufacture all of the initial requirements

Edgar Filing: Healthsport, Inc. - Form 10-K

for the ENLYTEN(TM) SPORTSTRIPS, ENLYTEN(TM) PEDIASTRIPS, FIX STRIPS, ENLYTEN(TM) ENERGY film strips and ENLYTEN(TM) SURVIVAL STRIPS and both Suppress Cough Strip products for itself and other third party distributors.

The PMG manufacturing facility is located in Ventura, California and is scheduled for completion in the summer of 2008. PMG will produce all of our product as well as 3rd party and private label film strip products. PMG's manufacturing process was developed by InnoZen and will be customized to meet the unique specifications of each client.

Using our own facilities, we can use a just-in-time inventory policy to manufacture only the minimum number of film strips necessary to meet retailers' orders. This reduces the sales and production cycle by several months and reduces cash requirements for inventory.

INTELLECTUAL PROPERTY

Patents and pending patent applications seek to protect new technologies we have developed in formulating, developing and manufacturing edible film strip products containing drug actives. Other techniques are protected as trade secrets. These new core technologies include novel methods of manufacturing film strips to create additional stability and to increase the amount of drug actives that can be delivered in a single film strip. We also seek to protect the delivery of the specific drug active ingredients in our edible film strips.

10

We have filed U.S. and foreign trademark and patent applications to protect product lines and general technology; they rely on a combination of intellectual property laws, nondisclosure agreements and other measures to protect proprietary rights. Currently, we have five United States patent applications pending; and we expect to file several more as new products are developed. We have also filed patent applications in several foreign countries and we also own various trademarks, including ENLYTEN, SPORTSTRIPS, RESTORE, SURVIVAL STRIPS, InnoZen, Suppress, and "Medicine in a Strip." Trademark registrations are available upon request.

SEGMENT REPORTING

We operate in one reportable segment.

Substantially all of our sales are currently domestic. We anticipate substantial international growth opportunities commencing in 2008.

CUSTOMERS

During 2007, we had one customer which accounted for 14% of consolidated sales.

BACKLOG

The Company currently maintains sufficient inventory to service orders within a short period and does not have a substantial backlog.

RESEARCH AND DEVELOPMENT

We have an active and ongoing research effort to develop new products and to make improvements to existing products. We also work with a number of customers to develop strip delivery systems for their products, which is generally reimbursed by the customer.

Edgar Filing: Healthsport, Inc. - Form 10-K

EMPLOYEES

At December 31, 2007, we had 42 full-time employees and we had four full-time employees at December 31, 2006.

Our employees are not represented by a labor union. We have experienced no work stoppage and believe that our employee relationships are good.

ITEM 1A: RISK FACTORS

Not applicable.

ITEM 2: PROPERTIES

The corporate offices are currently maintained in the office of the Company's accountant at no cost to the Company.

Enlyten executed a three-year operating lease which commenced on February 1, 2007 for 2,182 square feet of office space for its staff in Amherst, New York.

11

InnoZen leases its facility in Woodland Hills, California pursuant to a lease agreement which expires on January 1, 2010, at which time InnoZen has the option to extend the term for an additional year.

The Company leases a facility in Ventura, California which will become the PMG manufacturing facility. The lease commenced December 1, 2007 for seven years and two months until January 31, 2015. The Company has no cost for the lease obligation in January and February 2008 while they are installing the manufacturing equipment and preparing the facility for use.

ITEM 3: LEGAL PROCEEDINGS

To our knowledge, no legal proceeding is threatened against us.

On October 30, 2007, our wholly-owned subsidiary, Enlyten, Inc., filed a lawsuit against The Gatorade Company and PepsiCo, Inc. (collectively referred to as Gatorade) in the State of New York Supreme Court, County of Erie. The Complaint alleges that Gatorade has tortiously interfered with Enlyten's contractual agreement with the Buffalo Bills and with Enlyten's business relationships with various third parties including other NFL teams, in an attempt to wrongfully restrain trade. Enlyten is represented by Michael B. Powers of the law firm of Phillips Lytle, LLP in Buffalo, New York. The alleged interference has severely limited our ability to market and sell the ENLYTEN(TM) SPORT STRIP. The case is currently in the early discovery phase with a discover hearing scheduled for June 3, 2008.

ITEM 4: SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS

There were no matters submitted to a vote of security holders during the fourth quarter of 2007.

12

PART II

Edgar Filing: Healthsport, Inc. - Form 10-K

ITEM 5: MARKET FOR REGISTRANT'S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES

Our \$0.0001 par value per share common stock is traded in the over-the-counter market and is quoted on the National Association of Securities Dealers ("NASD") Over-The Counter Bulletin Board ("OTCBB") under the symbol "HSPO.OB." Previously we were quoted on the OTCBB under the symbols "ISPO.OB," "TSPT.OB," "LGST," and "RTTK." The following table sets forth the quarterly high and low daily close for our common stock as reported by the OTCBB for the two years ended December 31, 2007. The bids reflect inter-dealer prices without adjustments for retail mark-ups, mark-downs or commissions and may not represent actual transactions.

	HIGH	LOW
	----	---
2007		

Fourth quarter	\$ 1.55	\$ 0.52
Third quarter	\$ 2.09	\$ 0.95
Second quarter	\$ 2.45	\$ 1.48
First quarter	\$ 2.99	\$ 2.20
2006		

Fourth quarter	\$ 2.50	\$ 1.50
Third quarter	\$ 1.50	\$.75
Second quarter	\$ 4.00	\$ 1.05
First quarter	\$ 8.00	\$ 1.60

The OTCBB is a quotation service sponsored by the NASD that displays real-time quotes and volume information in over-the-counter ("OTC") equity securities. The OTCBB does not impose listing standards or requirements, does not provide automatic trade executions and does not maintain relationships with quoted issuers. A company traded on the OTCBB may face loss of market makers and lack of readily available bid and ask prices for its stock and may experience a greater spread between the bid and ask price of its stock and a general loss of liquidity with its stock. In addition, certain investors have policies against purchasing or holding OTC securities. Both trading volume and the market value of our securities have been, and will continue to be, materially affected by the trading on the OTCBB.

HOLDERS

At February 29, 2008, there were approximately 672 holders of record of our common stock including 11,076,149 shares in the public float.

13

DIVIDENDS

We have never paid cash dividends on our common stock and intend to utilize current and future resources to implement our plan of operations. It is not anticipated that cash dividends will be paid on our common stock in the foreseeable future.

SECURITIES AUTHORIZED FOR ISSUANCE UNDER EQUITY COMPENSATION PLANS

The following table summarizes certain information as of December 31, 2007, with respect to compensation plans (including individual compensation arrangements) under which our common stock is authorized for issuance:

Edgar Filing: Healthsport, Inc. - Form 10-K

Plan category	Number of securities to be issued upon exercise of outstanding options, warrants and rights	Weighted average exercise price of outstanding options, warrants and rights
Equity compensation plans		
approved by security holders:		
2000 Plan	--	\$ --
2006 Plan	3,605,390	1.53
	3,605,390	\$ --
	=====	

The Company has two Stock Option Plans; the Stock Option Plan dated in April 2000 and approved in April 2001 (the "2000 Plan") which authorizes the grant of options to purchase an aggregate of 15,000 shares; and the Stock Option Plan dated October 18, 2006 and approved in October 2006 (the "2006 Plan") which authorizes the grant of options to purchase an aggregate of 5,000,000 shares. On August 30, 2007, the Board of Directors authorized formation of a new plan with 4,000,000 shares. This plan has not been completed nor has it been approved by the stockholders. (Collectively the "Plans")

The material features of the Plans, the data for which is summarized under the equity compensation plans approved by security holders in the table above are summarized in Note 10 to the consolidated financial statements that appear in Item 8.

RECENT SALES OF UNREGISTERED SECURITIES

Sales during the first three quarters of the fiscal year were reported in Item 2 of Part II of the Form 10-QSB filed for each quarter.

During the fourth quarter:

- o We sold 1,087,500 shares for net cash proceeds in the amount of \$1,033,125;
- o We issued 5,000 shares for consulting fees valued at \$7,500; and
- o We issued 39,000 shares for accounts payable in the amount of \$39,000.

All of the shares issued were sold pursuant to an exemption from registration under Section 4(2) promulgated under the Securities Act of 1933, as amended.

14

ITEM 6: SELECTED FINANCIAL DATA

Not applicable.

ITEM 7: MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

HealthSport is publicly traded on the bulletin board market under the ticker symbol HSPO.OB. HealthSport is focused exclusively on the development, manufacturing, distribution and marketing of edible film strip technology. This technology system provides rapid dissolution and release of active ingredients

Edgar Filing: Healthsport, Inc. - Form 10-K

when the strip comes in contact with saliva in the mouth.

On May 4, 2007, the Company completed the acquisition of InnoZen through a merger of InnoZen with InnoZen Acquisition Sub, Inc. ("Acquisition Sub"), the Company's wholly owned subsidiary, all Delaware corporations, in exchange for 18,249,952 shares of the Company's common stock. In accordance with Delaware General Corporate Law and pursuant to the terms and conditions of the Merger Agreement, Acquisition Sub was merged with and into InnoZen, after which, InnoZen became the Company's wholly owned subsidiary and continues as the surviving corporation and the separate existence of Acquisition Sub ceased.

LIQUIDITY AND CAPITAL RESOURCES

At December 31, 2007 and 2006, we had current assets of \$2,411,410 and \$967,636; current liabilities of \$2,066,125 and \$57,848; and working capital of \$345,285 and \$909,788, respectively. We incurred a loss of \$9,847,000 during 2007, which included depreciation and amortization of \$989,167; amortization of non-cash stock compensation of \$2,484,042; and acquired research and development expense of \$847,336.

On February 1, 2008 HealthSport and InnoZen executed a Limited Liability Company Operating Agreement ("LLC Agreement") with Migami, Inc. ("Migami") for Pacific Manufacturing Group, LLC ("PMG"). Among other things, the LLC Agreement calls for Migami to contribute \$3,000,000 in cash to PMG for its intended 48% ownership and InnoZen licensed its technology to PMG for its 52% ownership. In summary, the agreement provides that PMG will manufacture all strip and other products for each member at cost plus 25%. As of April 8, 2008, \$1,000,000 of Migami's contribution has been received by PMG, and the remainder is expected to be received on or before April 30, 2008.

We currently anticipate that our only capital equipment requirements will be in PMG for which the \$3 million capital to be contributed by Migami should be adequate to fund PMG's requirements.

In 2007, the Company projected sales to be as high as \$10 million, based on forecasts for SPORTSTRIPS, PEDIASSTRIPS and FIX STRIPS. The alleged tortuous interference by Gatorade in our agreement with the Buffalo Bills, other NFL teams and NFL players substantially hindered our ability to market and sell our SPORTSTRIPS product, which was our first product to market. PEDIASSTRIPS and FIX STRIPS sales did not commence until the fourth quarter and were substantially below initial forecasts from consultants. At the end of the fourth quarter of 2007 the Company changed its sales direction and reduced staff with the goal of selling product through distributors rather than making all sales directly to our customers.

15

On March 11, 2008, we completed a five-year distribution deal with Unico Holdings, Inc. ("Unico"), wherein they will market our PEDIASSTRIPS product as well as negotiate for our electrolyte strips to be manufactured for private label usage. Unico markets its products through numerous sales channels, including large retail merchandisers, drug store chains, grocery stores and pharmaceutical distributors. Unico's customers include most of the larger retailers and distributors in the U.S. in each of these sales channels. The agreement calls for a minimum of \$22 million of product purchases over the five-year term in order for Unico to maintain its exclusive distribution right.

The Unico distribution deal is initially for PEDIASSTRIPS and should commence during the third quarter of 2008. We are attempting to establish similar arrangements for our SPORTSTRIPS and FIX STRIPS. In addition, we expect to begin sales of our ENERGY FILM STRIPS and SURVIVAL STRIPS before the end of 2008. The

Edgar Filing: Healthsport, Inc. - Form 10-K

Company is also seeking opportunities to establish film strip products for a number of products which are currently delivered in a different manner, such as liquids and pills. The Company expects this to develop into a large part of its business in the future.

The Company will continue to require substantial working capital until sales develop to the level required to support operations. The current level of overhead is approximately \$325,000 per month, excluding the PMG manufacturing operation. The Company is analyzing its current costs and is attempting to make additional cost reductions where possible. Current sales will not be adequate to support this level of operating costs. We estimate that sales will develop to the level necessary to be at or near cash flow break-even by the end of the third quarter of 2008. Based on this time-frame, the Company would need from \$2 to \$2.5 million to meet its minimum requirements, excluding PMG. The Company has made private placements of its common stock and as of April 10, 2008 had received \$610,000 in net proceeds. The Company expects to continue to make private placements of its common stock or to borrow additional funds as needed.

These conditions raise substantial doubt about the Company's ability to continue as a going concern. The consolidated financial statements do not include any adjustments that may result from the outcome of these uncertainties.

RESULTS OF OPERATIONS

2007 COMPARED TO 2006

REVENUES

In 2007 we had revenue from product sales of \$305,461 and revenue from license fees and royalties of \$133,363 for a total of \$438,824. In 2006 we had nominal product sales of \$1,137. The majority of 2007 was spent refining products and developing the means to distribute them. The 5-year distribution deal with Unico, discussed above, is the first major step and should result in substantial revenue growth commencing in the last half of 2008.

16

COSTS AND EXPENSES

Cost of product sold amounted to 75% of net product sales. The gross profit margin of 25% is lower than would be expected due to promotional discounts offered to new customers. Sales are net of discounts of \$160,422 (31% of gross sales). This amount should decline substantially in the future as customers begin to reorder without the higher level of promotions.

General and administrative expense ("G&A") amounted to \$3,405,508 in 2007 as compared to \$590,603 in 2006. In 2007, HealthSport had \$963,990 of G&A as compared to \$331,198 in 2006. The primary increases were payroll of \$279,660; legal, accounting and other professional fees of \$173,987; travel and entertainment of \$73,946; shareholder communications of \$52,949 and insurance of \$41,573. Enlyten and Health Strip had G&A costs of \$66,426 in 2007 and \$270,882 in 2006. The 2007 amount is amortization on Health Strip. The 2006 amount includes \$169,873 in consulting services; \$34,448 in payroll; and \$33,210 in amortization. The ongoing start-up costs in 2006 were included in marketing and selling expense in 2007. Nutraceuticals G&A amounted to \$106,094 in 2007, its first year of operation. This includes \$53,328 for amortization and \$30,501 for payroll. InnoZen's G&A amounted to \$2,269,298 for the eight months it was owned in 2007. This amount includes \$793,660 in amortization; \$653,249 in payroll and taxes; \$369,964 in legal, accounting and other professional services; and \$164,065 in insurance. With the formation of PMG, the payroll and benefits will

Edgar Filing: Healthsport, Inc. - Form 10-K

be allocated between the two entities. In addition, the legal, accounting and other professional fees should be substantially lower as it includes a two-year audit for periods during which InnoZen had very limited accounting staff.

Marketing and selling expense ("M&S") amounted to \$2,427,980 in 2007 and none during the initial start-up in 2006. The more significant components of M&S expenses are: professional fees of \$554,213, which includes endorsement and sponsorship fees of \$455,990; payroll expenses of \$573,325; advertising expense of \$654,852, including events and trade shows; and travel costs of \$58,277. Endorsements and sponsorship fees were substantially eliminated when we redirected our marketing plan in another direction at the end of 2007. Payroll costs will also be lower in 2008 as we have attempted to increase our product sales through existing distributors rather than have substantial direct sales.

Non-cash compensation amounted to \$2,484,042 in 2007 as compared to \$119,625 in 2006. This includes \$1,536,423 in amortization of the intrinsic value of common stock options and \$947,619 in amortization of common stock awards to employees, which are being amortized over the expected period of service.

Manufacturing costs amounted to \$617,665 in 2007 for the eight months we owned InnoZen. This represents the manufacturing costs not absorbed in inventory and should be substantially eliminated when the manufacturing volume increases. These costs will be on PMG for most of 2008.

Research and development costs amounted to \$1,175,450 in 2007 for the eight months we owned InnoZen. This includes \$847,336 in research and development cost which was acquired in the acquisition of InnoZen. The remainder is primarily testing services incurred in product development.

OTHER (INCOME) EXPENSE

Interest expense declined substantially in 2007 and is primarily the interest on capital leases on InnoZen. All notes in the Company in 2006 were converted into common stock by the end of 2006.

17

The beneficial conversion feature related to a \$500,000 loan in 2006 that was immediately convertible into common stock. Accordingly, the beneficial conversion feature was expensed when the note was funded.

Interest income increased to \$72,481 from \$8,137, primarily due to higher average cash balances during the year.

NEW ACCOUNTING STANDARDS

There are several new accounting pronouncements issued by the Financial Accounting Standards Board ("FASB") which are not yet effective. Each of these pronouncements, as applicable, has been or will be adopted by the Company. Management does not believe any of these accounting pronouncements has had or will have a material impact on the Company's financial position or operating results.

In September 2006, the FASB issued SFAS No. 157, "Fair Value Measures". This Statement defines fair value, establishes a framework for measuring fair value in generally accepted accounting principles, expands disclosures about fair value measurements, and applies under other accounting pronouncements that require or permit fair value measurements. SFAS No. 157 does not require any new fair value measurements. However, the FASB anticipates that for some entities, the application of SFAS No. 157 will change current practice. SFAS No. 157 is effective for fiscal years beginning after November 15, 2007, which for us would

Edgar Filing: Healthsport, Inc. - Form 10-K

be our fiscal year beginning January 1, 2008. We are currently evaluating the impact of SFAS No. 157 but do not expect that it will have a material impact on our financial statements.

In February 2007, the FASB issued SFAS No. 159, "The Fair Value Option for Financial Assets and Financial Liabilities." This statement permits entities to choose to measure many financial instruments and certain other items at fair value that are not currently required to be measured at fair value. SFAS No. 159 is effective for fiscal years beginning after November 15, 2007, which for the Company would be its fiscal year beginning January 1, 2008. The Company is currently evaluating the impact of SFAS No. 159, but does not expect that it will have a material impact on its financial statements.

In December 2007, the FASB issued SFAS No. 160, "Noncontrolling Interests in Consolidated Financial Statements, an amendment of ARB No. 51" ("SFAS 160"). SFAS 160 establishes accounting and reporting standards for the noncontrolling interests in a subsidiary and for the deconsolidation of a subsidiary. SFAS 160 is effective on January 1, 2009 for us. We are currently evaluating the impact of adopting SFAS 160.

CRITICAL ACCOUNTING POLICIES

The SEC issued Financial Reporting Release No. 60, "Cautionary Advice Regarding Disclosure about Critical Accounting Policies" ("FRR 60"), suggesting companies provide additional disclosure and commentary on their most critical accounting policies. In FRR 60, the SEC defined the most critical accounting policies as the ones that are most important to the portrayal of a company's financial condition and operating results, and require management to make its most

18

difficult and subjective judgments, often as a result of the need to make estimates of matters that are inherently uncertain. Based on this definition our most critical accounting policies include the valuation of intangibles, which affects their amortization and impairment calculations and stock-based compensation. The methods, estimates and judgments we use in applying these most critical accounting policies have a significant impact on the results we report in our consolidated financial statements.

INTANGIBLE ASSET VALUATION - The determination of the fair value of certain acquired assets and liabilities is subjective in nature and often involves the use of significant estimates and assumptions. Determining the fair values and useful lives of intangible assets requires the exercise of judgment. We may use our common stock to acquire assets and may use the Black-Scholes valuation method or another acceptable method to determine a valuation for the stock. The Black-Scholes valuation method calculates a volatility factor for the stock price and extrapolates a valuation using these criteria. This valuation method has generally proven effective for companies with established markets for their common stock; however, due to the lack of an established trading market for our common stock, in the opinion of management, this may result in an unduly high valuation for the stock.

STOCK-BASED COMPENSATION - We record the fair value of stock-based compensation to outside consultants as an operating expense. Historically, we have not recorded expenses relating to stock options granted to employees with an exercise price greater than or equal to market price at the time of grant. We have reported pro-forma net loss and loss per share in accordance with the requirements of SFAS 123 and SFAS 148. This disclosure shows net loss and loss per share as if we had accounted for our employee stock options under the fair value method of those statements. Pro-forma information is calculated using the

Edgar Filing: Healthsport, Inc. - Form 10-K

Black-Scholes pricing method on the date of grant. This option valuation model requires input of highly subjective assumptions. Because our employee stock options have characteristics significantly different from those of traded options, and because changes in the subjective input assumptions can materially affect the fair value estimate, in management's opinion, the existing model may not necessarily provide a reliable single measure of fair value of our employee stock options. We did not have any stock-based compensation during 2005; however, we did have stock-based compensation in 2006 and expect to have stock-based compensation in the future.

In December 2004, the FASB issued SFAS 123 (revised 2004), "Share-Based Payment" (SFAS 123(R)). Among other things, SFAS 123(R) requires expensing the fair value of stock options, previously optional accounting. For transition, upon adoption on January 1, 2006, SFAS 123(R) required expensing any unvested options and also required us to change the classification of certain tax benefits from option deductions to financing rather than operating cash flows.

OFF-BALANCE SHEET ARRANGEMENTS

The Company maintains its corporate office in the office of its accountant at no cost to the Company.

Enlyten has an operating lease for its office in Amherst, New York. The lease is for a three-year term beginning on February 1, 2007, expiring January 31, 2010 and covers 2,182 square feet.

19

InnoZen leases its office and current manufacturing facility in Woodland Hills, California. The lease expires on January 1, 2010 and has a one-year renewal option.

The Company leases a new manufacturing facility in Ventura, California which contains approximately 25,000 square feet. The lease term is from December 1, 2007 through January 31, 2015. No rent is due for January and February 2008 while the Company is working on equipment installation. This is the planned facility to be occupied by PMG.

TABULAR DISCLOSURE OF CONTRACTUAL OBLIGATIONS

	Payments due by Period (000's)				
	Total	Year 1	Year 2-3	Year 4-5	Over 5 years
Operating lease obligations:					
Enlyten office lease	\$ 61	\$ 29	\$ 32	\$ --	\$ --
InnoZen facility	303	144	159		
PMG facility	1,401	157	389	408	447
	1,765	330	580	408	447
	1,765	330	580	408	447
Capital lease obligations:					
InnoZen equipment	213	213	--	--	--
InnoZen software	107	23	47	37	--
	\$ 320	\$ 236	\$ 47	\$ 37	\$ --
	\$ 320	\$ 236	\$ 47	\$ 37	\$ --

ITEM 7A: QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Edgar Filing: Healthsport, Inc. - Form 10-K

Not applicable.

20

ITEM 8: FINANCIAL STATEMENTS

The Consolidated Financial Statements of HealthSport, Inc. and Subsidiaries together with the report thereon of Creason & Associates, P.L.L.C. for the years ended December 31, 2007 and 2006, is set forth as follows:

INDEX TO CONSOLIDATED FINANCIAL STATEMENTS

	Page
Report of Independent Registered Public Accounting Firm	22
Consolidated Balance Sheets	23
Consolidated Statements of Operations	24
Consolidated Statements of Stockholders' Equity (Deficit)	25
Consolidated Statements of Cash Flows	26
Notes to Consolidated Financial Statements	28

21

CREASON & ASSOCIATES, P.L.L.C.
7170 S. Braden Ave., Suite 100
Tulsa, OK 74136-6333

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

Board of Directors and Stockholders
HealthSport, Inc. and Subsidiaries:

We have audited the accompanying consolidated balance sheets of HealthSport, Inc. and Subsidiaries as of December 31, 2007 and 2006, and the related consolidated statements of operations, stockholders' equity (deficit) and cash flows for the years ended December 31, 2007 and 2006. These consolidated financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on these consolidated financial statements based on our audits.

We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. Our audits included consideration of internal control over financial reporting as a basis for designing audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion. An audit also includes examining, on a test basis, evidence supporting the amounts and disclosures in the consolidated financial statements, assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall consolidated financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.

Edgar Filing: Healthsport, Inc. - Form 10-K

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of HealthSport, Inc. and Subsidiaries at December 31, 2007 and 2006, and the results of their operations and their cash flows for the years ended December 31, 2007 and 2006, in conformity with accounting principles generally accepted in the United States of America.

The accompanying consolidated financial statements have been prepared assuming that HealthSport, Inc. and Subsidiaries will continue as a going concern. As discussed in Note 14 to the consolidated financial statements, HealthSport, Inc. has established its business of manufacturing and sale of electrolyte strips. However, there can be no assurance that the Company can obtain sufficient revenues to fund its operations and commitments or will be able to obtain sufficient funding to conduct its business plan. These conditions raise substantial doubt about HealthSport, Inc.'s ability to continue as a going concern. Management's plans regarding these matters are also described in Note 14. The consolidated financial statements do not include any adjustments that may result from the outcome of these uncertainties.

/s/ Creason & Associates, P.L.L.C.

Tulsa, Oklahoma

April 11, 2008

22

HEALTHSPORT, INC. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
DECEMBER 31, 2007 AND 2006

	2007	2006
	-----	-----
ASSETS		
Current assets:		
Cash and cash equivalents	\$ 167,323	\$ 318,144
Accounts receivable (less allowance of \$2,000 in 2007)	107,312	--
Stock subscription receivable	22,500	250,000
Inventory	1,402,530	145,742
Prepaid expenses and other assets	711,745	3,750
Note receivable - InnoZen, Inc.	--	250,000
	-----	-----
Total current assets	2,411,410	967,636
	-----	-----
Property and equipment, net	636,370	--
Patent costs and other intangible costs, net	20,308,545	1,898,506
Goodwill, net	10,326,948	1,785,998
Deposits	21,524	--
	-----	-----
Total assets	\$ 33,704,797	\$ 4,652,140
	=====	=====
LIABILITIES AND STOCKHOLDERS' EQUITY		
Current liabilities:		
Accounts payable	\$ 1,037,172	\$ 47,189
Accrued expenses	114,903	10,659
Current portion of capital lease obligations	217,954	--
Deferred revenue	696,096	--
	-----	-----

Edgar Filing: Healthsport, Inc. - Form 10-K

Total current liabilities	2,066,125	57,848
Capital lease obligations, less current portion	70,963	--
Total liabilities	2,137,088	57,848
Commitments and contingencies		
Stockholders' equity:		
Preferred stock: \$2.75 par value; authorized 2,000,000 shares no shares issued and outstanding	--	--
Common stock: \$.0001 par value; authorized 500,000,000 shares; 42,898,397 and 19,331,945 shares issued and outstanding at December 31, 2007 and 2006, respectively	4,290	1,933
Additional paid-in capital	67,980,373	29,452,595
Intrinsic value of common stock options	(2,860,229)	(1,151,711)
Common stock warrants	--	1,200
Accumulated deficit	(33,556,725)	(23,709,725)
Total stockholders' equity	31,567,709	4,594,292
Total liabilities and stockholders' equity	\$ 33,704,797	\$ 4,652,140

See accompanying notes to consolidated financial statements.

23

HEALTHSPORT, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATIONS
YEARS ENDED DECEMBER 31, 2007 AND 2006

	2007	2006
REVENUE		
Product sales	\$ 305,461	\$ 1,137
License fees, royalties and services	133,363	--
TOTAL REVENUES	438,824	1,137
COSTS AND EXPENSES:		
Cost of product sold	228,933	548
General and administrative expenses	3,405,808	590,603
Marketing and selling expense	2,427,980	--
Non-cash compensation	2,484,042	119,625
Manufacturing costs	617,665	--
Research and development cost	1,175,450	--
Asset impairments and abandonments	--	1,491
TOTAL COSTS AND EXPENSES	10,339,878	712,267
LOSS FROM OPERATIONS	(9,901,054)	(711,130)
OTHER (INCOME) EXPENSE:		
Interest expense	18,427	424,802
Beneficial conversion feature of convertible debenture	--	400,000
Interest income	(72,481)	(8,137)
Other (income) expense, net	(54,054)	816,665

Edgar Filing: Healthsport, Inc. - Form 10-K

NET LOSS BEFORE MINORITY INTEREST	(9,847,000)	(1,527,795)
MINORITY INTEREST	--	89,748
NET LOSS	\$ (9,847,000)	\$ (1,617,543)
NET LOSS PER SHARE, BASIC AND DILUTED	\$ (0.28)	\$ (0.32)
WEIGHTED AVERAGE SHARES OUTSTANDING, BASIC AND DILUTED	34,594,588	4,989,225

See accompanying notes to consolidated financial statements.

24

HEALTHSPORT, INC. AND SUBSIDIARIES

Consolidated Statements of Stockholders' Equity (Deficit)

Years ended December 31, 2007 and 2006

	COMMON SHARES	STOCK PAR	ADDITIONAL PAID-IN CAPITAL	COMMON STOCK WARRANTS	INTRINSIC VALUE OF COMMON STOCK OPTIONS
Balance, December 31, 2005	657,288	\$ 66	\$ 17,421,758	\$ 1,200	\$
Common stock issued for:					
Acquisition of Health Strip Solutions	1,425,000	143	2,771,107	--	
Acquisition of Cooley Nutraceuticals	375,000	37	806,213	--	
Settlement and sale of Idea Management Group	65,000	6	295,834	--	
Convertible debentures	14,879,574	1,488	5,521,867	--	
Accounts payable	741,000	74	151,385	--	
Services	389,083	39	781,675	--	(768,5
Cash proceeds	550,000	55	549,945	--	
Stock subscription	250,000	25	249,975	--	
Beneficial conversion feature of convertible notes payable	--	--	400,000	--	
Common stock options	--	--	502,836	--	(502,8
Amortize intrinsic value of common stock options	--	--	--	--	119,6
Net loss	--	--	--	--	
Balance, December 31, 2006	19,331,945	1,933	29,452,595	1,200	(1,151,7
Common stock issued for:					
Acquisition of InnoZen, Inc.	18,249,952	1,825	27,373,103	--	
Cash proceeds	4,951,500	495	6,542,550	--	
Stock subscription	15,000	2	22,498	--	
Stock awards	115,000	11	316,989	--	
Roayalty agreements	136,000	14	203,986	--	
Fix website and tradename	50,000	5	73,995	--	
Accounts payable	49,000	5	53,995	--	
Common stock warrants expired	--	--	1,200	(1,200)	

Edgar Filing: Healthsport, Inc. - Form 10-K

Intrinsic value of common stock options:					
Granted	--	--	3,939,462	--	(3,939,462)
Amortization	--	--	--	--	1,536,462
Reclassify unamortized stock awards	--	--	--	--	694,500
Net loss	--	--	--	--	--
Balance, December 31, 2007	42,898,397	\$ 4,290	\$ 67,980,373	\$ --	\$ (2,860,200)

See accompanying notes to consolidated financial statements.

25

HEALTHSPORT, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
YEARS ENDED DECEMBER 31, 2007 AND 2006

	2007	2006
	-----	-----
CASH FLOWS FROM OPERATING ACTIVITIES		
Net loss	\$ (9,847,000)	\$ (1,617,000)
Adjustment to reconcile net loss to net cash used in operating activities:		
Depreciation and amortization	989,167	16,000
Amortization of non-cash stock compensation	2,484,042	119,000
Acquired research and development cost	847,336	
Common stock issued for services	--	13,000
Beneficial conversion feature of convertible promissory note	--	400,000
Minority interest	--	89,000
Asset impairments	--	1,000
Change in assets and liabilities:		
Accounts receivable	(90,654)	
Inventory	(955,436)	(145,000)
Prepaid expenses and other assets	(300,075)	12,000
Accounts payable	694,573	193,000
Accrued expenses	205,886	433,000
Net cash used in operating activities	(5,972,161)	(483,000)
CASH FLOWS FROM INVESTING ACTIVITIES		
Loans to InnoZen, Inc. prior to acquisition	(500,000)	(250,000)
Cash received in excess of cash paid in acquisition of InnoZen, Inc.	16,832	
Legal fees associated with acquisition of Cooley Neutraceuticals, Inc.	(15,811)	
Acquisition of property and equipment	(325,585)	
Net cash used in investing activities	(824,564)	(250,000)
CASH FLOWS FROM FINANCING ACTIVITIES		
Loan proceeds	--	500,000
Collect stock subscription receivable	250,000	
Capital lease payments	(38,856)	
Loan repayment- related party	(108,285)	
Sale of common stock	6,543,045	550,000
Net cash provided by financing activities	6,645,904	1,050,000

Edgar Filing: Healthsport, Inc. - Form 10-K

NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS	(150,821)	316,
CASH AND CASH EQUIVALENTS, beginning of year	318,144	1,
	-----	-----
CASH AND CASH EQUIVALENTS, end of year	\$ 167,323	\$ 318,
	=====	=====

See accompanying notes to consolidated financial statements.

26

HEALTHSPORT, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS, CONTINUED
YEARS ENDED DECEMBER 31, 2007 AND 2006

	2007	2006
	-----	-----
SUPPLEMENTAL CASH FLOW INFORMATION		
CASH PAID FOR INTEREST AND INCOME TAXES:		
Interest	\$ 18,427	\$ --
Income taxes	--	--
NON-CASH INVESTING AND FINANCING ACTIVITIES:		
Issuance of common stock for:		
Prepaid royalty agreements	\$ 204,000	\$ --
Fix website and tradename	74,000	--
Stock subscription	22,500	--
Investment in Health Strip Solutions, LLC	--	2,771,250
Investment in Cooley Nutraceuticals, Inc.	--	806,250
Convertible notes and accrued interest	--	5,523,355
Accounts payable	54,000	151,459
Accounts payable and Idea Management Group, Inc.	--	295,840
Value of common stock options granted	--	502,836
Cancellation of common stock warrants	1,200	--
Acquisition of InnoZen, Inc.		
Current assets, excluding cash	584,993	--
Property and equipment	471,188	--
Goodwill and other intangible assets	27,643,918	--
Research and development	847,336	--
Other assets	10,583	--

Total assets	29,558,018	--
Liabilities assumed	(1,449,922)	--
Liabilities to HealthSport, Inc.	(750,000)	--

Purchase price (net assets acquired)	27,358,096	--
Common stock issued	(27,374,928)	--

Cash acquired in excess of cash paid	16,832	--
	=====	

See accompanying notes to consolidated financial statements.

27

HEALTHSPORT, INC. AND SUBSIDIARIES

Edgar Filing: Healthsport, Inc. - Form 10-K

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

NOTE 1: ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

PRINCIPLES OF CONSOLIDATION AND BASIS OF PRESENTATION

The consolidated financial statements include the accounts of HealthSport, Inc. ("HealthSport") and its wholly owned subsidiaries, Enlyten, Inc. ("Enlyten"), InnoZen, Inc. ("InnoZen"), Health Strip Solutions, LLC ("Health Strip"), Cooley Nutraceuticals, Inc. ("Nutraceuticals"), World Championship Poker, Inc. ("Poker"), Strategic Gaming Consultants, LLC ("Gaming") and Maxx Motorsports, Inc. ("Maxx") and Maxx's wholly owned subsidiary, Team Racing Auto Circuit, LLC ("TRAC"), collectively referred to as "the Company," "we," "us," or "the Companies". All significant inter-company balances and transactions have been eliminated in consolidation. Development of the Company's film strip product containing electrolytes represents the principal continuing operations of the Company.

On April 24, 2006, the Company filed a Definitive Information Statement pursuant to Section 14C which provided that effective May 15, 2006; 1) the Company's name would be changed to HealthSport, Inc.; 2) the Company's issued and outstanding shares would be reverse-split one share for each 200 shares; and 3) the Company's Certificate of Incorporation would be restated to reflect these amendments. These amendments were approved by the Company's Board of Directors and in writing by 52.33% of the Company's shareholders on March 31, 2006. Accordingly, effective May 15, 2006, the Company's name was changed to HealthSport, Inc., the Company's shares were reverse-split one for 200 and the Company's Certificate of Incorporation was restated to reflect these amendments. The change in outstanding shares and all references to shares have been retroactively restated for all periods included in this financial statement.

On May 4, 2007, the Company completed the acquisition of InnoZen through a merger of InnoZen with InnoZen Acquisition Sub, Inc. ("Acquisition Sub"), the Company's wholly owned subsidiary, all Delaware corporations, in exchange for 18,249,952 shares of the Company's common stock. In accordance with Delaware General Corporate Law and pursuant to the terms and conditions of the Merger Agreement, Acquisition Sub was merged with and into InnoZen, after which, InnoZen became the Company's wholly owned subsidiary and continues as the surviving corporation and the separate existence of Acquisition Sub ceased.

InnoZen is the preeminent formulator, developer and manufacturer of edible thin film strips that deliver drug actives and was the first company to deliver a drug active ingredient in a thin film strip when it completed the development of Chloraseptic(R) Sore Throat Relief Strips in June 2003. With Chloraseptic Relief Strips, InnoZen established a new process which prevented irritants and incorporated additional compounds to make the strips more suitable for various drug delivery needs. Relying on its expertise in the development of edible film strips that deliver drug actives, InnoZen moved forward with its proprietary technology to develop two new thin film strip products for cough. InnoZen launched its two new film strip products under its own Suppress(R) brand (<http://www.suppress.com>) in September 2004.

The acquisition was accounted for using the purchase method of

Edgar Filing: Healthsport, Inc. - Form 10-K

accounting and, accordingly, the consolidated statements of operations include the results of InnoZen beginning May 4, 2007. The assets acquired and the liabilities assumed were recorded at estimated fair values as determined by the Company's management based on information currently available and on current assumptions as to future operations.

ORGANIZATION

HealthSport was originally incorporated on July 25, 1985 in Delaware, and currently has the following wholly owned subsidiaries:

- o Enlyten, a Nevada corporation organized on November 28, 2006;
- o Health Strip, a Nevada limited liability corporation organized on February 13, 2006; acquired 80% on March 29, 2006, 10% on December 21, 2006 and the remaining 10% on December 27, 2006;
- o Nutraceuticals, a Nevada corporation organized on November 17, 2006; acquired on December 6, 2006;
- o InnoZen, a Nevada corporation organized on May 30, 2002; acquired on May 4, 2007;
- o Maxx, a Delaware corporation acquired on May 15, 2001 and currently inactive;
- o Poker, a Nevada corporation acquired on June 28, 2005 and currently inactive; and
- o Gaming, a Nevada limited liability corporation organized on November 8, 2004, and never activated.

NATURE OF BUSINESS

HealthSport is a holding company with six wholly owned subsidiaries.

Enlyten was formed to market and sell the Companies edible file strip products.

Health Strip in conjunction with InnoZen holds the proprietary technology for the formulation of a thin film electrolyte strip and has filed a provisional patent for this process. Electrolytes such as those found in Health Strip's ENLYTEN(TM) SPORTSTRIPS along with water, can be used in oral rehydration therapy to replenish the body's electrolyte levels after dehydration caused by exercise, diarrhea or vomiting. Health Strip and InnoZen also hold the proprietary technology for ENLYTEN(TM) SURVIVAL STRIPS which are formulated with antioxidants, non-cavity causing sweeteners, vitamins, herbal extracts, electrolytes, caffeine and other proven beneficial compounds.

Nutraceuticals holds the proprietary technology for the formulation of a nutritional supplement that quickly and effectively provides natural energy enhancers, caffeine, electrolytes, antioxidants and other essential vitamins and minerals. In conjunction with InnoZen, Nutraceuticals has designed our formulation to supply the body with a healthy boost in energy, while replenishing and maintaining the essential vitamins and minerals lost during activity, after a long flight, bad night of sleep or over indulgence of alcohol. Nutraceuticals has also designed a formulation which includes caffeine, electrolytes, antioxidants and other essential vitamins and minerals which is designed specifically for fast, effective and safe relief for those individuals who incorporate social drinking in their lifestyle.

On June 28, 2005, the Company acquired Poker. The Company initiated sales of a proprietary fantasy football format during September 2005 and believed it had completed the development stage on that date.

Edgar Filing: Healthsport, Inc. - Form 10-K

However, as a result of the late start in marketing the program, the Company returned all fees collected and cancelled the season. The Company then re-instituted the development stage for its businesses from the original inception date of September 9, 2004. While the Company may elect to operate the fantasy football program for the 2008 or later season, the principal focus of the Company will be on development, marketing and distribution of the electrolyte strip products. The Company impaired the goodwill associated with Poker to the \$50,000 amount which was determined to be the fair value of the investment at December 31, 2005. No additional impairment was considered necessary at December 31, 2007.

Gaming was assigned no value when acquired and is currently inactive.

Idea Management Group, Inc. ("IMGI") was a concept development company that internally created projects in the fields of professional sports, motion pictures, publishing, licensed merchandise and other entertainment products for distribution into the global marketplace. IMGI was sold to a former CEO during 2006.

Maxx, through its wholly owned subsidiary, TRAC, planned to develop, own, operate, and sanction an automotive racing league designed to provide content for television and tracks while expanding the existing base of racing fans. This operation was discontinued on August 26, 2003.

On May 15, 2006, the Company changed its name to HealthSport, Inc. On November 8, 2004, the Company changed its name to Idea Sports Entertainment Group, Inc. On May 15, 2001, the Company changed its name from Logisoft Corp. to Team Sports Entertainment, Inc.

CASH AND CASH EQUIVALENTS

The Company considers all cash on hand, cash in banks and all highly liquid debt instruments purchased with a maturity of three months or less to be cash and cash equivalents.

REVENUE RECOGNITION

Revenue from product sales is recognized when the related goods are shipped and all significant obligations have been satisfied. Revenue from services is recognized when the services are performed. At December 31, 2007, the Companies had \$512,500 in deferred license fee revenue and \$183,596 received on product orders which have not shipped. The deferred license fee revenue will be recognized when earned and the product revenue will be recognized when the product is shipped.

ACCOUNTS RECEIVABLE AND ALLOWANCE FOR DOUBTFUL ACCOUNTS

Trade accounts receivable are recorded at the invoiced amount and do not bear interest. The allowance for doubtful accounts is the Company's best estimate of the amount of probable credit losses in the Company's existing accounts receivable. The Company determines the allowance based on historical write-off experience and reviews its allowance for doubtful accounts quarterly. Account balances are charged off against the allowance when the Company believes it is probable the receivable will not be recovered.

30

INVENTORY

Inventories consist of finished electrolyte strip products, work-in-process and raw materials, and are stated at the lower of average cost or market.

Edgar Filing: Healthsport, Inc. - Form 10-K

CONCENTRATION OF CREDIT RISK

Cash is maintained at financial institutions. The Federal Deposit Insurance Corporation ("FDIC") insures accounts at each institution for up to \$100,000. At times, cash balances may exceed the FDIC insurance limit of \$100,000.

STOCK OPTION PLANS

Until December 31, 2005, the Company accounted for stock-based employee compensation arrangements in accordance with the provisions of Accounting Principles Board ("APB") Opinion No. 25, "Accounting for Stock Issued to Employees" and complied with the disclosure provisions of SFAS No.123, "Accounting for Stock-Based Compensation." Under APB No. 25, employee compensation cost was recognized over the vesting period based on the excess, if any, on the date of grant of the fair value of the Company's shares over the employee's exercise price. When the exercise price of the employee share options was less than the fair value price of the underlying shares on the grant date, deferred stock compensation was recognized and amortized to expense in accordance with Financial Accounting Standards Board ("FASB") Interpretation No. 44 over the vesting period of the individual options. Accordingly, if the exercise price of the Company's employee options equaled or exceeded the market price of the underlying shares on the date of grant, no compensation expense was recognized. Options or shares awards issued to non-employees are valued using the fair value method and expensed over the period services are provided.

In December 2004, the FASB issued SFAS 123(R), "Share-Based Payment," which requires that the compensation cost relating to share-based payment transactions (including the cost of all employee stock options) be recognized in the financial statements. That cost will be measured based on the estimated fair value of the equity or liability instruments issued. SFAS 123(R) covers a wide range of share-based compensation arrangements including share options, restricted share plans, performance-based awards, share appreciation rights, and employee share purchase plans. SFAS 123(R) replaces SFAS 123, "Accounting for Stock-Based Compensation," and supersedes APB Opinion No. 25, "Accounting for Stock Issued to Employees." As originally issued, SFAS 123 established as preferable a fair-value-based method of accounting for share-based payment transactions with employees. However, that pronouncement permitted entities to continue applying the intrinsic-value model of APB Opinion 25, provided that the financial statements disclosed the pro forma net income or loss based on the preferable fair-value method. This statement is effective as of the first reporting period that begins after December 15, 2005. Accordingly, the Company adopted SFAS 123(R) in the 1st quarter of 2006. Thus, the Company's financial statements reflected an expense for (a) all share-based compensation arrangements granted on or after January 1, 2006 and for any such arrangements that are modified, cancelled, or repurchased after that date, and (b) the portion of previous share-based awards for which the requisite service had not been rendered as of that date, based on the grant-date estimated fair value. The Company had no unvested options outstanding on January 1, 2006, and the option and stock awards granted during 2006 were included in the financial statements as required by SFAS 123(R).

The Black-Scholes option valuation model was developed for use in estimating the fair value of traded options that have no vesting restrictions and are fully transferable. In addition, option valuation

Edgar Filing: Healthsport, Inc. - Form 10-K

models require the input of highly subjective assumptions including the expected stock price volatility. Because HealthSport's options have characteristics significantly different from those of traded options, and because changes in the subjective input assumptions can materially affect the fair value estimate, in management's opinion the existing models may not necessarily provide a reliable single measure of the fair value of HealthSport's options.

DEFERRED INCOME TAXES

Deferred income taxes are provided for temporary differences between financial and tax reporting in accordance with the liability method under the provisions of SFAS No. 109, "Accounting for Income Taxes." A valuation allowance is recorded to reduce the carrying amounts of deferred tax assets unless management believes it is more likely than not that such assets will be realized.

EARNINGS (LOSS) PER COMMON SHARE

Earnings (loss) per common share are calculated under the provisions of SFAS No. 128, "Earnings per Share" ("SFAS No. 128"), requires the Company to report both basic earnings per share, which is based on the weighted-average number of common shares outstanding, and diluted earnings per share, which is based on the weighted-average number of common shares outstanding plus all potentially dilutive shares outstanding. At December 31, 2007 and 2006, all exercisable common stock equivalents were antidilutive and are not included in the earnings (loss) per share calculations. Accordingly, basic and diluted earnings per share are the same for all periods presented.

ESTIMATES

The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

RECENT ACCOUNTING PRONOUNCEMENTS

There are several new accounting pronouncements issued by the Financial Accounting Standards Board ("FASB") which are not yet effective. Each of these pronouncements, as applicable, has been or will be adopted by the Company. Management does not believe any of these accounting pronouncements has had or will have a material impact on the Company's financial position or operating results.

In September 2006, the FASB issued SFAS No. 157, "Fair Value Measures". This Statement defines fair value, establishes a framework for measuring fair value in generally accepted accounting principles, expands disclosures about fair value measurements, and applies under other accounting pronouncements that require or permit fair value measurements. SFAS No. 157 does not require any new fair value measurements. However, the FASB anticipates that for some entities, the application of SFAS No. 157 will change current practice. SFAS No. 157 is effective for fiscal years beginning after November 15, 2007, which for us would be our fiscal year beginning January 1, 2008. The Company is currently evaluating the impact of SFAS No. 157 but does not expect that it will have a material impact on its financial statements.

In February 2007, the FASB issued SFAS No. 159, "The Fair Value Option

Edgar Filing: Healthsport, Inc. - Form 10-K

for Financial Assets and Financial Liabilities." This statement permits entities to choose to measure many financial instruments and certain other items at fair value that are not currently required to be measured at fair value. SFAS No. 159 is effective for fiscal years beginning after November 15, 2007, which for the Company would be its fiscal year beginning January 1, 2008. The Company is currently evaluating the impact of SFAS No. 159, but does not expect that it will have a material impact on its financial statements.

In December 2007, the FASB issued SFAS No. 160, "Noncontrolling Interests in Consolidated Financial Statements, an amendment of ARB No. 51" ("SFAS 160"). SFAS 160 establishes accounting and reporting standards for the noncontrolling interests in a subsidiary and for the deconsolidation of a subsidiary. SFAS 160 is effective on January 1, 2009 for the Company. The Company is currently evaluating the impact of adopting SFAS 160.

PROPERTY AND EQUIPMENT

Property and equipment are stated at cost, less accumulated depreciation. Depreciation is recorded using the straight-line method over the estimated useful lives of the respective assets (generally three to seven years). Maintenance and repairs are charged to operations when incurred. Betterments and renewals are capitalized. When property and equipment are sold or otherwise disposed of, the asset account and related accumulated depreciation account are relieved, and any gain or loss is included in operations.

FAIR VALUE DETERMINATION

Financial instruments consist of cash, marketable securities, accounts and notes receivable, accounts payable, accrued expenses and short-term borrowings. The carrying amount of these financial instruments approximates fair value due to their short-term nature or the current rates at which the Company could borrow funds with similar remaining maturities.

GOODWILL, PATENT COSTS AND OTHER INTANGIBLE COSTS

The Company records goodwill and intangible assets arising from business combinations in accordance with SFAS No. 141 "Business Combinations" ("SFAS 141") which requires that the purchase method of accounting be used for all business combinations initiated after June 30, 2001. SFAS 141 also specifies the criteria applicable to intangible assets acquired in a purchase method business combination to be recognized and reported apart from goodwill.

The Company accounts for goodwill and intangible assets in accordance with SFAS 142. In accordance with SFAS 142, the Company no longer amortizes goodwill. SFAS 142 requires that goodwill and intangible assets with indefinite useful lives no longer be amortized, but instead be tested at least annually for impairment. SFAS 142 also requires that intangible assets with definite useful lives be amortized over their respective estimated useful lives to their estimated residual values, and be reviewed for impairment.

33

SHIPPING AND HANDLING COSTS

Shipping and handling costs are reported in selling and marketing costs in the accompanying consolidated statements of operations. These costs amounted to \$28,017 in 2007 and none in 2006.

ADVERTISING COSTS

Edgar Filing: Healthsport, Inc. - Form 10-K

The Company expenses advertising costs as incurred. The Company recorded advertising costs of \$740,985 and \$26,721 for the years ended December 31, 2007 and 2006, respectively.

RECLASSIFICATIONS

Certain prior year amounts have been reclassified to conform to current year presentation.

NOTE 2: ACQUISITIONS

INNOZEN, INC.

On May 4, 2007, the Company completed the acquisition of InnoZen through a merger of InnoZen with InnoZen Acquisition Sub, Inc. ("Acquisition Sub"), the Company's wholly owned subsidiary, all Delaware corporations, in exchange for 18,249,952 shares of the Company's common stock. In accordance with Delaware General Corporate Law and pursuant to the terms and conditions of the Merger Agreement, Acquisition Sub was merged with and into InnoZen, after which, InnoZen became the Company's wholly owned subsidiary and continues as the surviving corporation and the separate existence of Acquisition Sub ceased. Subsequently, InnoZen re-domiciled in Nevada.

InnoZen is the preeminent formulator, developer and manufacturer of edible thin film strips that deliver drug actives and was the first company to deliver a drug active ingredient in a thin film strip when it completed the development of Chloraseptic(R) Sore Throat Relief Strips in June 2003. With Chloraseptic Relief Strips, InnoZen established a new process which prevented irritants and incorporated additional compounds to make the strips more suitable for various drug delivery needs. Relying on its expertise in the development of edible film strips that deliver drug actives, InnoZen moved forward with its proprietary technology to develop two new thin film strip products for cough. InnoZen launched its two new film strip products under its own Suppress(R) brand (<http://www.suppress.com>) in September 2004.

The acquisition was accounted for using the purchase method of accounting and, accordingly, the consolidated statements of operations include the results of InnoZen beginning May 4, 2007. The assets acquired and the liabilities assumed were recorded at estimated fair values as determined by the Company's management based on information currently available and on current assumptions as to future operations. A summary of the estimated fair value of assets acquired and liabilities assumed in the acquisition follows:

Current assets, excluding cash and cash equivalents	\$	584,993
Property and equipment		471,188
Other assets		10,583
Intangible assets		19,102,968
Goodwill		8,540,950
Research and development cost		847,336

Total assets		29,558,018
Liabilities assumed		(1,449,922)
Liabilities to HealthSport		(750,000)

Purchase price (net assets acquired)		27,358,096
Common stock issued		(27,374,928)

Cash acquired in excess of cash paid	\$	16,832
		=====

Edgar Filing: Healthsport, Inc. - Form 10-K

34

Unaudited pro forma results of operations for the years ended December 31, 2007 and 2006, as if the Company and InnoZen had been combined as of the beginning of the periods follows. The pro forma results include estimates and assumptions which management believes are reasonable. However, pro forma results are not necessarily indicative of the results that would have occurred if the business combination had been in effect on the dates indicated, or which may result in the future.

	2007	2006
	-----	-----
Net revenues	\$ 849,119	\$ 823,937
Net loss	(10,400,865)	(3,571,337)
Net loss per share, basic and diluted	\$ (0.26)	\$ (0.15)

The audited financial statements for InnoZen, Inc. for the two years ended December 31, 2006 are included as an exhibit to Form 8-K/A dated May 4, 2007 and filed on September 20, 2007.

HEALTH STRIP

On March 29, 2006, the Company entered into a Unit Purchase Agreement with the majority of the unit holders of Health Strip to acquire 80% of Health Strip in exchange for 500,000 shares of the Company's common stock. Health Strip, in conjunction with InnoZen, holds certain proprietary technology and trade secrets for the formulation of a film strip product containing electrolytes to replenish the body while under physical stress (the "electrolyte strip"). Health Strip had contracted with InnoZen to manufacture its electrolyte strip product prior to its acquisition on May 4, 2007.

At the time it was acquired, Health Strip did not have any tangible assets or liabilities, but it did have the trade secret for an electrolyte replenishment system and the rights to file for a patent of this process. Accordingly, Health Strip recorded \$1,125,000 as an intangible asset for trade secret costs, 80% of which is equal to the value of the Company's common stock issued on the date of the transaction. The Company commenced amortization of its total trade secret costs in July 2006 over seventeen years. The Company will periodically evaluate the unamortized balance of the trade secret costs and record an impairment loss if warranted.

During December 2006, the Company issued 925,000 shares of its common stock to acquire the remaining 20% of Health Strip, which was valued at \$1,871,250, based upon the trading price of the Company's stock on the acquisition date. This amount was reduced by the book value of the associated minority interest of \$135,252 and the resulting \$1,735,998 was recorded as goodwill.

35

NUTRACEUTICALS

On December 6, 2006, the Company issued 375,000 shares of its common stock to acquire 100% of Nutraceuticals. At the time it was acquired, Nutraceuticals had a receivable for \$3,750 and did not have any liabilities, but it did have certain proprietary technology and trade secrets for the formulation of a nutritional supplement that quickly and effectively provides natural energy enhancers, caffeine, electrolytes, antioxidants and other essential vitamins and minerals. In conjunction with InnoZen, Nutraceuticals has designed the Company's formulation to supply the body with a healthy boost in energy, while

Edgar Filing: Healthsport, Inc. - Form 10-K

replenishing and maintaining the essential vitamins and minerals lost during activity, after a long flight, bad night of sleep or over indulgence of alcohol. This transaction was recorded based upon the trading price of the Company's common stock on the date of the purchase and the resulting \$806,250 was allocated \$3,750 to accounts receivable and \$802,500 to an intangible asset for trade secret costs. The Company commenced amortization of the trade secret costs over seventeen years, the life in January 2007. The Company will periodically evaluate the unamortized balance of the trade secret costs and record an impairment loss if warranted.

In June 2007, the Company issued 50,000 shares of its common stock, valued at \$74,000, and a warrant to acquire 50,000 shares of its common stock at \$2.25 per share to acquire the trade name for HANGOVER FIX(R), FIX STRIPS(TM) and the website and related domain names.

INACTIVE OPERATIONS

POKER

On June 28, 2005, the Company issued 19,250 shares of its common stock, which were valued at \$295,544 using the Black-Scholes valuation model, to acquire Poker, whose principal asset is the rights to a proprietary fantasy football format, with the working title, Vegas Roll'em(TM) Fantasy Football ("Vegas Roll'em"). Poker recorded the investment of \$295,544 as goodwill. While the Company may still pursue the project for the 2008 season or later, its principal focus is on the electrolyte strip products. The Company elected to impair its investment in the goodwill associated with Poker to the \$50,000 amount determined to be the fair value of the investment at December 31, 2005. The Company believes no additional impairment is required at December 31, 2007.

IMGI

On September 9, 2004, the Company acquired all of the issued and outstanding common stock of IMGI in exchange for warrants to acquire 75,000 shares of its common stock at an exercise price of \$20 per share. IMGI is a South Carolina corporation organized on July 28, 2004 and had no prior operations. This transaction was valued at \$1,200, which was the amount the sellers of IMGI paid for IMGI's common stock. The warrants expired in 2007.

Effective August 29, 2006, the Company issued 65,000 shares of its common stock to a former CEO of the Company and transferred the stock of IMGI, including liabilities of \$295,840 to the former CEO. The liabilities included \$291,913 which the former CEO claimed was due to him and affiliates for costs advanced in the original formation of IMGI.

GAMING

On October 27, 2004, the Company acquired all of the issued and outstanding memberships of Gaming in exchange for warrants to acquire 3,750 shares of its common stock at an exercise price of \$20 per share. Gaming had no prior operations and had no assets. Accordingly, the transaction was recorded with no value. Gaming has never been activated. The warrants expired in 2007.

36

NOTE 3: INVENTORY

Inventory at December 31, 2007 and 2006, consists of the following:

2007

2006

Edgar Filing: Healthsport, Inc. - Form 10-K

Raw materials	\$ 395,239	\$ --
Work in progress	169,016	--
Finished goods	838,275	145,742
	-----	-----
Total	\$1,402,530	\$ 145,742
	=====	=====

NOTE 4: NOTE RECEIVABLE - INNOZEN, INC.

On December 26, 2006, the Company loaned InnoZen \$250,000 pursuant to the letter of intent to acquire InnoZen executed on December 20, 2006. The loan was interest free for a term of 210 days. An additional \$500,000 was loaned to InnoZen by May 4, 2007 and upon completion of the acquisition on that date, the loan became a part of the intercompany balance which eliminates in consolidation.

NOTE 5: PROPERTY AND EQUIPMENT

Property and equipment at December 31, 2007 consists of the following (none at December 31, 2006):

	TOTAL	SUBJECT TO CAPITAL LEASE
	-----	-----
Office furniture and equipment	\$ 83,393	\$ --
Computer software	101,150	99,172
Manufacturing equipment	487,578	416,695
Leasehold improvements	39,561	38,880
	-----	-----
	711,682	554,747
Accumulated depreciation	(75,312)	(55,683)
	-----	-----
	\$ 636,370	\$ 499,064
	=====	=====

NOTE 6: INTANGIBLE ASSETS

The Company accounts for goodwill and intangible assets in accordance with SFAS 142. Goodwill and other intangible assets are tested annually, at a minimum, for impairment. Patent costs are amortized over their life of seventeen years from the date the patent application is filed. Patent costs include the costs allocated to the proprietary technology for the formulation of thin film electrolyte strip products and associated legal costs. Trade secrets include costs allocated to our formulations and are being amortized over seventeen years. Trademarks represent the cost of acquired trademarks, which are not being amortized. Client lists represents the cost of acquired client lists which are being amortized over five years.

The Company's intangible assets consist of the following at December 31, 2007 and 2006:

Edgar Filing: Healthsport, Inc. - Form 10-K

	2007	2006
	-----	-----
Patent costs and other intangible assets:		
Patent and trade secret costs	\$ 19,155,124	\$ 1,931,716
Trademarks	1,188,365	--
Client lists	846,000	--
Web site	65,675	--
	-----	-----
	21,255,164	1,931,716
Accumulated amortization	(946,619)	(33,210)
	-----	-----
Net	\$ 20,308,545	\$ 1,898,506
	=====	=====
Goodwill	\$ 10,326,948	\$ 1,785,998
	=====	=====

At December 31, 2007, accumulated amortization includes \$828,176 for patent and trade secret costs, \$112,800 for client lists and \$5,643 for web site costs. At December 31, 2006, all accumulated amortization is for patent and trade secret costs.

NOTE 7: CAPITAL LEASES

During the year ended December 31, 2005, InnoZen entered into a sale-leaseback agreement, under which it sold certain manufacturing equipment and leased it back for a period of three years. The leaseback was accounted for as a capital lease and no gain was recognized on the transaction. In 2007, the Company entered into a five year lease agreement for manufacturing software. The following is a schedule by years of future minimum lease payments under capital leases together with the present value of the net minimum lease payments as of December 31, 2007 (none at December 31, 2006).

Total minimum lease payments:	
Year ended December 31, 2008	\$ 236,772
Year ended December 31, 2009	23,352
Year ended December 31, 2010	23,352
Year ended December 31, 2011	23,352
Year ended December 31, 2012	13,622

	320,450
Amount representing interest	(31,533)

Present value of minimum lease payments	288,917
Less current obligations	(217,954)

Non-current obligations under capital lease	\$ 70,963
	=====

38

The leases cover equipment and software with a cost of \$554,747 and accumulated depreciation of \$55,683 at December 31, 2007.

NOTE 8: CONVERTIBLE PROMISSORY NOTES

Activity in convertible promissory notes for the year ended December 31, 2006 is

Edgar Filing: Healthsport, Inc. - Form 10-K

as follows (none at December 31, 2007):

	Principal	Accrued Interest
	-----	-----
Balance, January 1, 2006	\$ 4,530,309	\$ 68,244
Loan proceeds	500,000	--
Accrued interest	--	424,802
Converted to common stock	(5,030,309)	(493,046)
	-----	-----
Balance, December 31, 2006	\$ --	\$ --
	=====	=====

In June 2006, the Company issued a 12%, one-year convertible promissory note payable for \$500,000 and received advances on this loan in the amount of \$448,600 in June 2006 and \$51,400 in October 2006. The note is convertible into restricted common shares at the rate of \$1.00 per share. Management has determined that this note qualifies as conventional convertible debt pursuant to APB No. 14, "Accounting for Convertible Debt and Debt Issued with Stock Purchase Warrants" and EITF 98-5, "Accounting for Convertible Securities with Beneficial Conversion Features or Contingently Adjustable Conversion Ratios" and accordingly the embedded conversion option is not a derivative. The Company computed a beneficial conversion value of \$400,000 based on the quoted stock price on the grant date of \$1.80 per share. The \$400,000 was credited to additional paid-in capital and charged to interest expense when the agreement was funded since the convertible promissory note could be converted upon issuance.

At the end of September 2006, the Company issued 14,362,500 shares of its common stock for convertible promissory notes in the principal amount of \$4,530,309 plus accrued interest of \$475,972. These convertible promissory notes included a provision which reduced the conversion price per share to the lowest price the Company received from the sale of its common stock while the notes were outstanding. Prior to the notes being converted to common stock, the Company sold common stock at a price below the price at which all of these notes were converted. Accordingly, SFAS No. 84 "Induced Conversions of Convertible Debt," does not apply to the conversion of these notes. At the end of December 2006, the Company issued 517,074 shares of its common stock for the remaining convertible debenture of \$500,000 principal and accrued interest of \$17,074.

39

NOTE 9: INCOME TAXES

HealthSport has not recorded a deferred tax benefit or expense for the years ended December 31, 2007 and 2006, as all net deferred tax assets have a full valuation allowance.

Actual income tax benefit applicable to net loss before income taxes is reconciled with the "normally expected" federal income tax as follows:

	2007	2006
	-----	-----
"Normally expected" income tax benefit	\$ 3,348,000	\$ 549,900
Increase (decrease) in taxes resulting from:		
State income taxes net of federal income tax benefit	325,000	53,400
Nondeductible meals and entertainment	(8,400)	(200)
Valuation allowance	(3,664,600)	(603,100)
	-----	-----

Edgar Filing: Healthsport, Inc. - Form 10-K

Actual income tax expense	\$ --	\$ --
	=====	=====

The net deferred taxes at December 31, 2007 and 2006 are comprised of the following:

Net operating loss carryforward	\$ 14,321,900	\$ 10,657,300
Start-up cost carryforward	827,600	827,600
	-----	-----
	15,149,500	11,484,900
Valuation allowance	(15,149,500)	(11,484,900)
	-----	-----
Net deferred tax asset	\$ --	\$ --
	=====	=====

HealthSport has available unused net operating loss carryforwards and capitalized start-up costs of \$40,456,000 which will expire in various periods from 2008 to 2027, some of which may be limited as to the amount available on an annual basis.

NOTE 10: COMMON STOCK OPTIONS AND WARRANTS

In April 2000, HealthSport adopted its 2000 Stock Option Plan (the "2000 Plan") and the Company's Board of Directors approved the same. HealthSport shareholders approved the 2000 Plan in April 2001. The 2000 Plan was established to advance the interests of HealthSport and its stockholders by attracting, retaining and motivating key personnel. The Board of Directors, or a committee that it appoints, is authorized to grant options to purchase the common stock of HealthSport, not to exceed an aggregate of 15,000 shares. The Board of Directors, or a committee that it appoints, is also authorized to establish the exercise price and vesting terms of individual grants under the 2000 Plan. The 2000 Plan terminates in April 2010.

40

On October 18, 2006, HealthSport adopted its 2006 Stock Option Plan (the "2006 Plan") and the Company's Board of Directors and shareholders approved the 2006 Plan. The 2006 Plan was established to advance the interests of HealthSport and its stockholders by attracting, retaining and motivating key personnel. The Board of Directors, or a committee that it appoints, is authorized to grant options to purchase the common stock of HealthSport, not to exceed an aggregate of 5,000,000 shares. The Board of Directors, or a committee that it appoints, is also authorized to establish the exercise price and vesting terms of individual grants under the 2006 Plan. The 2006 Plan terminates on October 18, 2011.

Options granted under the 2000 Plan or the 2006 Plan (collectively the "Plans") may be either "incentive stock options" intended to qualify as such under the Internal Revenue Code, or "non-qualified stock options." HealthSport expects that most options granted pursuant to the Plans will be subject to vesting over a three or four-year period, such as 25% increments on each annual grant date anniversary, during which the optionee must continue to be an employee of HealthSport. The Board or the committee, if applicable, may choose to impose different vesting requirements or none at all. Options outstanding under the Plans have a maximum term of up to ten years.

The Plans also provide that all options that are not vested will become vested upon a change in control, unless the options are either assumed or substituted with equivalent options. In addition, unvested options become vested, after a change in control, if an optionee is subject to involuntary termination other

Edgar Filing: Healthsport, Inc. - Form 10-K

than for cause during that optionee's remaining vesting period after a change in control. The Plan further provides that all options will be forfeited 30 days after employment terminates or six months in the case of death or disability.

A summary of stock option activity under the Plans during the years ended December 31, 2007 and 2006 is as follows.

	2007		2006	
	Shares	Weighted average exercise price	Shares	Weighted average exercise price
Outstanding, beginning of year	100,000	\$ 2.25	7,500	\$ 200.00
Granted	3,505,390	1.51	100,000	2.25
Exercised	--	--	--	--
Forfeited/expired	--	--	(7,500)	200.00
Outstanding, end of year	3,605,390	\$ 1.53	100,000	\$ 2.25
Options exercisable at year end	3,585,390	\$ 1.53	100,000	\$ 2.25
Shares available for grant	1,409,610		4,915,000	

In addition, as of December 31, 2007 and 2006, fully-vested options to acquire 510,000 shares and 325,000 shares of the Company's common stock were outstanding at an average exercise price of \$2.07 and \$1.86, respectively. These options were granted to consultants and are not issued pursuant to the Plans.

On September 9, 2004, the Company issued 75,000 warrants to acquire its common stock at \$20, to acquire IMGI. The warrants expired on August 31, 2007.

41

On November 15, 2004, the Company issued 3,750 warrants to acquire its common stock at \$20, to acquire Gaming. The warrants expired on November 15, 2007.

Data concerning stock options at December 31, 2007 and 2006 follows:

Options Outstanding			
Exercise Price	Number of Options	Weighted- Average Remaining Contractual Life (years)	Number of Options Exercisable
Year ended December 31, 2007			
\$0-1.10	100,000	1.70	100,000
\$1.36-1.50	2,980,390	2.37	2,980,390
\$2.20-2.41	975,000	1.91	975,000
\$2.50-2.70	60,000	3.33	40,000
Year ended December 31, 2006			
\$ 1.10	100,000	2.75	100,000

Edgar Filing: Healthsport, Inc. - Form 10-K

2.20	225,000	2.65	225,000
2.25	100,000	2.83	100,000

The fair value of each option on the date of grant is estimated using the Black Scholes option valuation model. The following weighted-average assumptions were used for options granted during the year ended December 31, 2007 and 2006:

	2007 ----	2006 ----
Expected term	1-5 years	2-3 years
Expected average volatility	103.77%	146.12%
Expected dividend yield	0%	0%
Risk-free interest rate	4.75%	4.75%
Expected annual forfeiture rate	0%	0%

NOTE 11: STOCKHOLDERS' EQUITY

PREFERRED STOCK--The Company is authorized to issue up to 2,000,000 shares of Series A non-voting, cumulative preferred stock with a par value of \$2.75. At December 31, 2007, no preferred stock was issued or outstanding.

A 6% cumulative dividend would be payable quarterly to stockholders of record on the last day of the month prior to the dividend date. The Series A preferred stock has a liquidation preference over HealthSport's common stock as well as any other classes of stock established by HealthSport.

42

COMMON STOCK - The Company is authorized to issue up to 500,000,000 shares of common stock with a par value of \$.0001. At December 31, 2007, 42,898,397 shares were issued and outstanding.

REVERSE-SPLIT OF COMMON STOCK - Effective May 15, 2006, pursuant to shareholder approval the Company's shares were reverse-split one share for each 200 shares outstanding.

INTRINSIC VALUE OF COMMON STOCK OPTIONS - Intrinsic value of common stock options includes the computed fair value of the compensation element of common stock options for employees, consultants and directors. This cost is being amortized over the average expected exercise period.

COMMON STOCK TRANSACTIONS - 2007

- o 18,249,952 shares of common stock were issued to acquire 100% of InnoZen, which was valued at \$27,374,928;
- o 4,951,500 shares of common stock were issued for net cash proceeds of \$6,543,045;
- o 15,000 shares of common stock were issued for a stock subscription receivable of \$22,500 which was collected in January 2008;
- o 115,000 shares of common stock were issued to employees and consultants as stock awards valued at \$317,000;
- o 136,000 shares of common stock were issued for royalty agreements valued at \$204,000;
- o 50,000 shares of common stock were issued for the Fix website and tradenames, valued at \$74,000;
- o 49,000 shares of common stock were issued for accounts payable in

Edgar Filing: Healthsport, Inc. - Form 10-K

the amount of \$54,000.

COMMON STOCK TRANSACTIONS - 2006

- o 1,425,000 shares of common stock were issued to acquire 100% of Health Strip which was valued at \$2,771,250;
- o 375,000 shares of common stock were issued to acquire Nutraceuticals which was valued at \$806,250;
- o 65,000 shares of common stock were issued to a former CEO and director to settle a claim for reimbursement of \$291,913 in costs which were claimed to have been advanced in the formation of IMGI, in addition, IMGI was also transferred to the former CEO with a total valuation of \$295,840;
- o 14,879,574 shares of common stock issued for convertible notes payable and accrued interest of \$5,523,355;
- o 741,000 shares of common stock issued for accounts payable of \$151,459;
- o 389,083 shares of common stock issued for \$13,214 in current services and \$768,500 in services to be performed over the next two years;
- o 550,000 shares of common stock issued for \$550,000 in cash; and
- o 250,000 shares of common stock issued for a stock subscription receivable in the amount of \$250,000, which was collected on January 8, 2007.

43

NOTE 12: RELATED PARTY TRANSACTIONS

2007 TRANSACTIONS

InnoZen repaid a loan to a principal shareholder and affiliate in the amount of \$108,285 after the acquisition of InnoZen was completed.

2006 TRANSACTIONS

Effective August 20, 2006, the Company issued 65,000 shares of its common stock to a former CEO of the Company and transferred the stock of IMGI, including liabilities of \$295,840 to the former CEO. The liabilities included \$291,913 which the former CEO claimed was due to him and affiliates for costs advanced in the original formation of IMGI.

During the year ended December 31, 2006, the Company had three different part-time CEOs. In aggregate they were paid \$16,000 during the year.

NOTE 13: COMMITMENTS AND CONTINGENCIES

The Company maintains its corporate office in the office of its accountant at no cost to the Company.

In January 2007, the Company executed a three-year lease agreement for 2,182 square feet of office space in Amherst, New York for the Enlyten office.

InnoZen leases its office and current manufacturing facility in Woodland Hills,

Edgar Filing: Healthsport, Inc. - Form 10-K

California. The lease expires on January 1, 2010 and has a one-year renewal option.

The Company leased a new manufacturing facility in Ventura, California which contains approximately 25,000 square feet. The lease term is from December 1, 2007 through January 31, 2015. No rent is due for January and February 2008 while the Company is working on equipment installation. This is the facility which PMG will occupy and the rent should be paid by PMG.

Future minimum lease payments for operating leases are: 2008 - \$330,000; 2009 - \$381,000; 2010 - \$199,000; 2011 - \$202,000; 2012 - \$206,000; and thereafter - \$447,000.

The Company has the following royalty agreements:

1. Royalty agreement expiring October 31, 2008 of 0.5% of sales of the ENLYTEN(TM) SPORTSTRIPS. Annual minimum royalty of \$18,000 and maximum of \$75,000;
2. Royalty agreement expiring October 31, 2008 of 0.5% of sales of the ENLYTEN(TM) SPORTSTRIPS. Annual minimum royalty of \$15,000 and maximum of \$50,000;
3. Royalty agreement for an indefinite period of 0.5% of sales of the ENLYTEN(TM) SPORTSTRIPS. Annual minimum royalty of \$36,000 and maximum of \$100,000;
4. Royalty agreement for an indefinite period of 1.0% of the first \$100,000 in sales of the ENLYTEN(TM) SPORTSTRIPS and 0.5% of the next \$150,000,000 in sales of the ENLYTEN(TM) SPORTSTRIPS.
5. Royalty agreement for an indefinite period of 1.0% of the first \$20,000,000 in sales of the FIX STRIPS and ENLYTEN(TM) ENERGY strips and 0.5% of the next \$80,000,000 in sales of the FIX STRIPS and ENLYTEN(TM) ENERGY strips.

44

The Company had agreements in place for racing car design and construction, team sales brokerage and broadcasting which were not formally terminated when the Company discontinued these operations. The Company does not expect any additional liability from these agreements.

NOTE 14: GOING CONCERN

At December 31, 2007 and 2006, we had current assets of \$2,411,410 and \$967,636; current liabilities of \$2,066,125 and \$57,848; and working capital of \$345,285 and \$909,788, respectively. We incurred a loss of \$9,847,000 during 2007, which included depreciation and amortization of \$989,167; amortization of non-cash stock compensation of \$2,484,042; and acquired research and development expense of \$847,336.

On February 1, 2008 HealthSport and InnoZen executed a Limited Liability Company Operating Agreement ("LLC Agreement") with Migami, Inc. ("Migami") for Pacific Manufacturing Group, LLC ("PMG"). Among other things, the LLC Agreement calls for Migami to contribute \$3,000,000 in cash to PMG for its intended 48% ownership and InnoZen licensed its technology to PMG for its 52% ownership. In summary, the agreement provides that PMG will manufacture all strip and other products for each member at cost plus 25%. As of April 8, 2008, \$1,000,000 of Migami's contribution has been received by PMG and the remainder is expected to be received on or before April 30, 2008.

We currently anticipate that our only capital equipment requirements will be in

Edgar Filing: Healthsport, Inc. - Form 10-K

PMG for which the \$3 million capital to be contributed by Migami should be adequate to fund PMG's requirements.

In 2007, the Company projected sales to be as high as \$10 million, based on forecasts for SPORTSTRIPS, PEDIASSTRIPS and FIX STRIPS. The alleged tortuous interference by Gatorade in our agreement with the Buffalo Bills, other NFL teams and NFL players substantially hindered our ability to market and sell our SPORTSTRIPS product, which was our first product to market. PEDIASSTRIPS and FIX STRIPS sales did not commence until the fourth quarter and were substantially below initial forecasts from consultants. At the end of the fourth quarter of 2007 the Company changed its sales direction and reduced staff with the goal of selling product through distributors rather than making all sales directly to our customers.

On March 11, 2008, we completed a five-year distribution deal with Unico Holdings, Inc. ("Unico"), wherein they will market our PEDIASSTRIPS product as well as negotiate for our electrolyte strips to be manufactured for private label usage. Unico markets its products through numerous sales channels, including large retail merchandisers, drug store chains, grocery stores and pharmaceutical distributors. Unico's customers include most of the larger retailers and distributors in the U.S. in each of these sales channels. The agreement calls for a minimum of \$22 million of product purchases over the five-year term in order for Unico to maintain its exclusive distribution right.

The Unico distribution deal is initially for PEDIASSTRIPS and should commence during the third quarter of 2008. We are attempting to establish similar arrangements for our SPORTSTRIPS and FIX STRIPS. In addition, we expect to begin sales of our ENERGY FILM STRIPS and SURVIVAL STRIPS before the end of 2008. The Company is also seeking opportunities to establish film strip products for a number of products which are currently delivered in a different manner, such as liquids and pills. The Company expects this to develop into a large part of its business in the future.

45

The Company will continue to require substantial working capital until sales develop to the level required to support operations. The current level of overhead is approximately \$325,000 per month, excluding the PMG manufacturing operation. The Company is analyzing its current costs and is attempting to make additional cost reductions where possible. Current sales will not be adequate to support this level of operating costs. We estimate that sales will develop to the level necessary to be at or near cash flow break-even by the end of the third quarter of 2008. Based on this time-frame, the Company would need from \$2 to \$2.5 million to meet its minimum requirements, excluding PMG. The Company has made private placements of its common stock and as of April 10, 2008 had received \$610,000 in net proceeds. The Company expects to continue to make private placements of its common stock or to borrow additional funds as needed.

These conditions raise substantial doubt about the Company's ability to continue as a going concern. The consolidated financial statements do not include any adjustments that may result from the outcome of these uncertainties.

NOTE 15: SUBSEQUENT EVENTS

On February 1, 2008 HealthSport and InnoZen executed a Limited Liability Company Operating Agreement ("LLC Agreement") with Migami, Inc. ("Migami") for Pacific Manufacturing Group, LLC ("PMG"). Among other things, the LLC Agreement calls for Migami to contribute \$3,000,000 in cash to PMG for its intended 48% ownership and InnoZen licensed its technology to PMG for its 52% ownership. In

Edgar Filing: Healthsport, Inc. - Form 10-K

summary, the agreement provides that PMG will manufacture all strip and other products for each member at cost plus 25%. As of April 8, 2008, \$1,000,000 of Migami's contribution has been received by PMG and the remainder is expected to be received on or before April 30, 2008.

On March 11, 2008, we completed a five-year distribution deal with Unico Holdings, Inc. ("Unico"). Unico markets its products through numerous sales channels, including large retail merchandisers, drug store chains, grocery stores and pharmaceutical distributors. Unico's customers include most of the largest retailers and distributors in the U.S. in each of these sales channels. The agreement calls for a minimum of \$22 million of product purchases over the five-year term in order for Unico to maintain its exclusive distribution right.

46

ITEM 9: CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE

None.

ITEM 9A(T): CONTROLS AND PROCEDURES

(a) Evaluation of Disclosure Controls and Procedures

Disclosure controls and procedures are designed to ensure that information required to be disclosed in the reports that are filed or submitted under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the Securities and Exchange Commission's rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed in the reports that are filed under the Exchange Act is accumulated and communicated to management, including the principal executive officer, as appropriate to allow timely decisions regarding required disclosure. Under the supervision of and with the participation of management, including the principal executive officer and principal financial officer, the Company has evaluated the effectiveness of the design and operation of its disclosure controls and procedures as of December 31, 2007, and, based on its evaluation, our principal executive officer and our principal financial officer have concluded that these controls and procedures are effective.

(b) Changes in Internal Controls

There have been no significant changes in internal controls or in other factors that could significantly affect these controls subsequent to the date of the evaluation described above, including any corrective actions with regard to significant deficiencies and material weaknesses.

(c) Management's Annual Report on Internal Control Over Financial Reporting

The management of the Company is responsible for establishing and maintaining adequate internal control over financial reporting and for the assessment of the effectiveness of internal control over financial reporting. As defined by the SEC, internal control over financial reporting is defined in Rule 13a-15(f) or 15d-15(f) promulgated under the Exchange Act as a process designed by, or under the supervision of, the Company's principal executive and principal financial officers and effected by the Company's board of directors, management and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. The Company's internal control over financial reporting is supported by written

Edgar Filing: Healthsport, Inc. - Form 10-K

policies and procedures that: (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the Company's assets; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles and that receipts and expenditures of the Company are being made only in accordance with authorizations of the Company's management and directors; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the Company's assets that could have a material effect on the financial statements.

47

The Company's internal control system was designed to provide reasonable assurance to the Company's management and board of directors regarding the preparation and fair presentation of published financial statements. All internal control systems, no matter how well designed, have inherent limitations which may not prevent or detect misstatements. Therefore, even those systems determined to be effective can provide only reasonable assurance with respect to financial statement preparation and presentation. Projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Management conducted an evaluation of the effectiveness of the Company's internal control over financial reporting as of December 31, 2007. In making this assessment, management used the framework set forth in the report entitled "Internal Control-Integrated Framework" issued by the Committee of Sponsoring Organizations of the Treadway Commission, or COSO. The COSO framework summarizes each of the components of a company's internal control system, including (i) the control environment, (ii) risk assessment, (iii) control activities, (iv) information and communication, and (v) monitoring. Based on this evaluation, management concluded that the Company's internal control over financial reporting was not effective as of December 31, 2007, due primarily to a lack of segregation of duties.

This annual report does not include an attestation report of our registered public accounting firm regarding internal control over financial reporting. Management's report was not subject to attestation by our registered public accounting firm pursuant to temporary rules of the Securities and Exchange Commission that permits us to provide only management's report in this annual report.

ITEM 9B: OTHER INFORMATION

Pursuant to General Instruction B of Form 8-K, any reports previously or in the future submitted under Item 2.02 (Results of Operations and Financial Condition) are not deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 and the Company is not subject to the liabilities of that section, unless the Company specifically states that the information is to be considered "filed" under the Exchange Act or incorporates it by reference into a filing under the Securities Act or Exchange Act. If a report on Form 8-K contains disclosures under Item 2.02, whether or not the report contains disclosures regarding other items, all exhibits to such report relating to Item 2.02 will be deemed furnished, and not filed, unless the registrant specifies, under Item 9.01 (Financial Statements and Exhibits), which exhibits, or portions of exhibits, are intended to be deemed filed rather than furnished pursuant to this instruction. The Company is not incorporating, and will not incorporate, by reference these reports into a filing under the Securities Act of 1933, as amended, or the Exchange Act of 1934, as amended.

Edgar Filing: Healthsport, Inc. - Form 10-K

On December 11, 2007, Daniel J. Kelly resigned as Acting CEO and M.E. "Hank" Durschlag assumed this position while the Company sought a new CEO. On March 1, 2008, Robert Kusher became CEO and Mr. Durschlag resigned his position as Acting CEO. The biographies of each of the above is included in Item 10 herein.

48

PART III

ITEM 10: DIRECTORS, EXECUTIVE OFFICERS, PROMOTERS, CONTROL PERSONS AND CORPORATE GOVERNANCE; COMPLIANCE WITH SECTION 16(a) OF THE EXCHANGE ACT

EXECUTIVE OFFICERS AND DIRECTORS

The following section sets forth the names, ages and current positions with the Company held by the Directors, Executive Officers and Significant Employees; together with the year such positions were assumed. There is no immediate family relationship between or among any of the Directors, Executive Officers or Significant Employees, and we are not aware of any arrangement or understanding between any Director or Executive Officer and any other person pursuant to which he was elected to his current position. Each Executive Officer will serve until he or she resigns or is removed or otherwise disqualified to serve, or until his or her successor is elected and qualified. We currently have three Directors.

NAME ----	AGE ---	POSITION AND TERM -----
Robert Kusher	44	CEO starting March 1, 2008
Daniel J. Kelly	46	Acting CEO and President starting January 1, 2007; became a Director on May 2, 2007; resigned as Acting CEO on December 11, 2007
Hank Durschlag	44	Director since September 11, 2006; acting CEO from December 11, 2007 until March 1, 2008; Acting CFO since December 11, 2007
Robert S. Davidson	41	Director since May 4, 2007; CEO of InnoZen, Inc.
Matthew Burns	38	Director since May 4, 2007; COO of HealthSport since May 4, 2007
Michael D. Pruitt	47	Director since May 2, 2007
Gary Thomas	48	Vice President Sales, Enlyten since January 1, 2007.

49

ROBERT KUSHER - Mr. Kusher founded Hollywood Healthcare Corp. in 1998 with the purpose of distributing pharmaceuticals and diabetes products via mail order to patients nationwide. Under his leadership, the company has grown to become one of the country's premier providers of insulin infusion pumps, diabetes specialty products, and mail order pharmaceuticals. In 2001, the company changed its name to Logimedix.

Previously, Mr. Kusher founded Home Medical Supply, Inc., which was the first diabetes supply provider accepting Medicare assignment nationwide. Over the course of ten years, he successfully expanded the company's service offerings to include a pharmacy, a lab supply company, a home health nursing company and a

Edgar Filing: Healthsport, Inc. - Form 10-K

group physician practice. The company was a recognized leader in the industry generating over \$25 million in revenues when Mr. Kusher sold the company to MiniMed, Inc. in 1997. Mr. Kusher joined MiniMed as Vice President and Operations Manager for the Florida facility and assisted in the transition process until he founded Hollywood Healthcare Corp. in 1998.

Mr. Kusher is active in the healthcare industry and is a founding member of the Assisted Living Pharmacy Association, a for profit group purchasing organization representing a network of pharmacies across the country. His other healthcare related business ventures include Star Medical Distributors, LLC, a wholesale provider of consumable medical supplies with facilities in Florida and Georgia and two full body CT scanning centers in the Mid-Atlantic area that operate under the name Virtual Physical. Mr. Kusher holds a Bachelor of Business Administration Degree with an emphasis on management and marketing from Florida International University.

DANIEL J. KELLY - Became Acting CEO and President on January 1, 2007. Mr. Kelly began his business career approximately 20 years ago managing and advising Jim Kelly, his brother and Pro Football Hall of Fame Quarterback. Mr. Kelly also owns and serves as the President of Jim Kelly Enterprises, Inc., a company started over 15 years ago. In 1988 Mr. Kelly negotiated the most lucrative player contract in NFL history (at that time) for Jim. Mr. Kelly has 20 years experience in marketing, promotions and celebrity endorsements and continues to work with such companies as Coors, Miller Lite, LA Weightloss and Ameriquest. Mr. Kelly received his bachelor's degree from the University of Houston and was a prominent member of the NFL Quarterback Club, serving on the Sponsorship and Marketing Committees that negotiated comprehensive, multi-year deals with major US companies such as McDonalds, VISA, Footlocker and MBNA Bank. He is the vice chairman of the Kelly for Kids Foundation.

HANK DURSCHLAG - was appointed a Director of the Company on September 11, 2006. Mr. Durschlag is the co-developer of the Enlyten electrolyte sports strips and co-authored the patent, "Edible Film for Transmucosal Delivery of Nutritional Supplements". Mr. Durschlag has extensive experience in the fields of healthcare and sports medicine, with specific emphasis on novel drug delivery systems. In addition, Mr. Durschlag is a partner in Greenville, South Carolina based GlucoTec, Inc., a developer and manufacturer of an FDA Class II Medical Device designed to regulate blood glucose levels in an acute care setting via both intravenous and subcutaneous delivery of insulin and other fluids. Mr. Durschlag has also co-authored patents in this area. Previously, Mr. Durschlag served as Vice President of Sales and Marketing for Diabetes Management Services, Inc., a durable medical equipment distributor with specific treatment modules in women's health and pregnancy. Mr. Durschlag holds a bachelors degree from California University of Pennsylvania and an MBA from Clemson University.

50

ROBERT STEVEN DAVIDSON - Mr. Davidson has been the Company's Chairman of the Board since May 4, 2007. Since May 2002, Mr. Davidson has also served as the President, Chief Executive Officer and a director of InnoZen. From January 2002 through July 2005, Mr. Davidson was President and Chief Executive Officer of Zengen, Inc. Mr. Davidson has over eight years of experience in the biopharmaceutical industry. From September 1998 to December 2001, Mr. Davidson was the chief executive officer of Gel Tech, L.L.C., where he raised capital for the market launch and distribution of the Zicam product line. He led the marketing team that took Zicam from an unknown entity to one of the top medications in its class. He also implemented and launched line extensions to strengthen the brand name and increase company value. From October 1994 to August 1998, Mr. Davidson was the chief executive officer of Biotem Cytotechnologies, Inc., a biopharmaceutical research and development company. Mr. Davidson received his B.S. degree with a concentration in Biological Life

Edgar Filing: Healthsport, Inc. - Form 10-K

Sciences from The University of the State of New York, (Excelsior College). He has a Masters Certificate in Applied Project Management from Villanova University and received his Masters of Public Health (Homeland Security) from American Military University, Virginia. Mr. Davidson is a certified Performance Enhancement Specialist through the National Academy of Sports Medicine.

MATTHEW BURNS - Mr. Burns has served as the Chief Operating Officer and a Director of the Company since May 4, 2007. Mr. Burns has also been an officer and director of InnoZen since April 2004. Prior to joining InnoZen and its parent Zengen, from July 2001 to February 2002, Mr. Burns was an associate attorney at Morgan Lewis & Bockius, LLP, where he worked in the firm's business and finance practice group in the Los Angeles office. Prior to joining Morgan Lewis, Mr. Burns worked as an associate attorney in the corporate finance group at Morrison & Foerster's San Francisco office. Prior to joining Morrison & Foerster, Mr. Burns worked as an associate attorney in the corporate practice at Holland & Knight in Tampa, Florida. His law practice concentrated on mergers and acquisitions and corporate finance for companies in a variety of industries, including life sciences and technology. Mr. Burns has also provided counsel to public and private companies on general corporate law, corporate governance and securities matters. Mr. Burns received his J.D. from Stetson University of College of Law in 1995 and his B.A. in Finance from the University of South Florida in 1992.

MICHAEL D. PRUITT - Michael Pruitt, a long-time entrepreneur with a proven track record, possesses the expertise to evaluate potential investments, form key relationships and recognize a strong management team. Mr. Pruitt founded Avenel Financial Group, a boutique financial services firm concentrating on emerging technology company investments. The business succeeded immediately, and in order to grow Avenel Financial Group to its full potential and better represent the company's ongoing business model, he formed Avenel Ventures, an innovative technology investment and business development company. In the late 1980s, Mr. Pruitt owned Southern Cartridge, Inc., which he eventually sold to MicroMagnetic, Inc., where he continued working as Executive Vice President and a Board member until Southern Cartridge was sold to Carolina Ribbon in 1992. From 1992 to 1996, Mr. Pruitt worked in a trucking firm where he was instrumental in increasing revenues from \$6 million to \$30 million. The firm was sold in 1996 to Priority Freight Systems. Between 1997 and 2000, Mr. Pruitt assisted several public and private companies in raising capital, recruiting management and preparing companies to go public or be sold. He was the CEO, President and Chairman of the Board of Onetravel Holdings, Inc. (formerly RCG Companies), a publicly traded holding company formerly listed on the AMEX. Mr. Pruitt received a Bachelor of Arts degree from Coastal Carolina University in Conway, South Carolina, where he sits on the Board of Visitors of the Wall School of Business. He is also Managing Director of Cain Capital Advisors. Mr. Pruitt is currently CEO and director of Chanticleer Holdings, Inc. (CEEH.OB) and CEO and director of Syzygy Entertainment, Ltd. (SYZG.OB).

51

GARY THOMAS - Gary Thomas joined Enlyten as Vice President and Director of Sales in January 2007. Mr. Thomas has had 28 years experience in the sales industry. For the 10 years prior to joining Enlyten, Mr. Thomas was with Acosta, the world's largest food broker. From 2000 through the end of 2006, Mr. Thomas held the position of Director of HBC/GM Northeast Region. He has managed such accounts as Wegman's, Tops, Kinney Drug and CVS, and handled sales of such product lines as Energizer, L'Oreal, Neutrogena and KAO Brands. Under Mr. Thomas' supervision, Acosta recorded \$200+ million in annual sales revenue.

AUDIT COMMITTEE

The Board of Directors had determined that Michael D. Pruitt met the

Edgar Filing: Healthsport, Inc. - Form 10-K

requirements of a financial expert and served as Chairman of the Audit Committee since he became a director on May 2, 2007. Mr. Pruitt is independent as specified in Item 7(d)(3)(iv) of Schedule 14A under the Exchange Act and meets the requirements of a financial expert.

The registrant has a separately designated standing audit committee established in accordance with Section 3(a)(58)(A) of the Exchange Act, which is made up solely of Mr. Pruitt since May 2, 2007.

COMPLIANCE WITH SECTION 16(a) OF THE EXCHANGE ACT

Section 16(a) of the Securities Exchange Act of 1934, as amended, requires the Company's executive officers, directors and persons who own more than ten percent of the Company's common stock to file initial reports of ownership and changes in ownership with the SEC. Additionally, SEC regulations require that the Company identify any individuals for whom one of the referenced reports was not filed on a timely basis during the most recent fiscal year or prior fiscal years. To the Company's knowledge, based solely on a review of reports furnished to it, the Directors were late filing their Form 3s in 2007 when they became Directors.

CODE OF ETHICS

The Company has completed a number of acquisitions since September 2004, the largest being InnoZen in May 2007, and expects to include the adoption of a code of ethics on its agenda during 2008.

NOMINATING COMMITTEE

The Company does not currently have a standing nominating committee or committee performing similar functions. The full Board of Directors participates in the consideration of director nominees.

ITEM 11: EXECUTIVE COMPENSATION

The Compensation Committee of the Board of Directors deliberates executive compensation matters to the extent they are not delegated to the Chief Executive Officer.

52

The following table shows the compensation of the Company's Chief Executive Officer and each executive officer whose total cash compensation exceeded \$100,000 for the three years ended December 31, 2007.

SUMMARY COMPENSATION TABLE

Name and principal position	Year	Salary (\$)	Stock awards (\$)	Option awards (\$)	All other compensation (\$)	Total (\$)
Robert Kusher (CEO since March 1, 2008)	2007	N/A	N/A	N/A	N/A	N/A
	2006	N/A	N/A	N/A	N/A	N/A
	2005	N/A	N/A	N/A	N/A	N/A
M.E. "Hank" Durschlag (d) (Interim CEO from 12/11/07 to 3/1/08; Acting CFO since	2007	\$100,000	\$ --	\$ --	\$ 2,810	\$ 102,810
	2006	72,000	--	--	--	72,000
	2005	N/A	N/A	N/A	N/A	N/A

Edgar Filing: Healthsport, Inc. - Form 10-K

12/11/07)

Daniel J. Kelly (Acting CEO from January 1, 2007 until December 11, 2007) (a)	2007	\$203,646	\$ 27,500	\$289,200	\$ --	\$ 520,346
	2006	N/A	\$ 5,500	\$ 5,910	\$ 32,500	\$ 43,910
	2005	N/A	N/A	N/A	N/A	N/A
Robert S. Davidson (CEO of InnoZen from May 4, 2007) (b)	2007	\$120,250	\$ --	\$110,650	\$ --	\$ 230,900
	2006	N/A	N/A	N/A	N/A	N/A
	2005	N/A	N/A	N/A	N/A	N/A
Matthew Burns (COO of HealthSport from May 4 2007) (b)	2007	\$120,250	\$ --	\$110,650	\$ --	\$ 230,900
	2006	N/A	N/A	N/A	N/A	N/A
	2005	N/A	N/A	N/A	N/A	N/A
Gary Thomas (Vice President Sales of Enlyten since January 1, 2007) (c)	2007	\$117,708	\$ 11,748	\$ 33,192	\$ --	\$ 162,648
	2006	N/A	N/A	N/A	N/A	N/A
	2005	N/A	N/A	N/A	N/A	N/A

(a) In 2007 and 2006, the amount for the stock award represents the amortization of Mr. Kelly's 10% share of the stock granted to Jim Kelly for his appearance fees. The option award represents the amortization of the option granted to Mr. Kelly. All other compensation in 2006 represents the amount paid to Jim Kelly Enterprises, Inc. Mr. Kelly is owner and President of Jim Kelly Enterprises, Inc. and was acting as a consultant to the Company during 2006. At December 31, 2007, Mr. Kelly had \$8,854 in accrued salary not included in the table above.

(b) The option award for Mr. Davidson and Mr. Burns represents the eight month amortization of the stock option granted to them upon the purchase of InnoZen by HealthSport. The total amortization period is three years. At December 31, 2007, Mr. Davidson and Mr. Burns each had \$3,083 in accrued salary not included in the table above.

(c) The stock grant amount represents the amortization of the assigned value of the stock grant, which is being amortized over two years. The option award amount represents the amortization of the assigned value of the option grant, which is being amortized over two years. At December 31, 2007, Mr. Thomas has \$2,083 in accrued salary not included in the table above.

53

(d) Mr. Durschlag earned \$2,810 in royalties on sales of the Enlyten products.

Columns for bonus, non-equity incentive plan compensation and nonqualified deferred compensation earnings have been omitted from the table above as all amounts are zero.

NARRATIVE DISCLOSURE TO SUMMARY COMPENSATION TABLE

Compensation levels and amounts are determined by the board of directors based on amounts paid to executives in similar sized companies with similar responsibilities. Stock options are valued utilizing the Black-Scholes valuation method.

Mr. Kusher became Chief Executive Officer of the Company on March 1, 2008. Mr. Kusher's compensation will be \$240,000 per year for two years with benefits to include health insurance, four weeks vacation and reimbursement of all

Edgar Filing: Healthsport, Inc. - Form 10-K

reasonable out-of-pocket expenses. Mr. Kusher is to be awarded 500,000 shares of our common stock that vests when we receive \$750,000 in debt or equity into the Company from his efforts. Mr. Kusher has also been granted an option to purchase 1,000,000 shares of our common stock at an exercise price of \$1.00 per share which is exercisable on March 1, 2009 and an option to purchase 1,000,000 shares of our common stock at an exercise price of \$1.50 per share which is exercisable on March 1, 2010. The options expire three years from the vesting date.

Mr. Kelly became President and Acting Chief Executive Officer of the Company on January 1, 2007. Mr. Kelly's compensation for 2007 was \$212,500 and he received \$1,000 per month insurance reimbursement until health insurance was available for employees. Mr. Kelly's compensation increased to \$262,500 in 2008. In addition, Mr. Kelly was granted a stock option for 400,000 shares exercisable at \$2.25 per share in January 2007, which expires in three years. Mr. Kelly will also be reimbursed for all reasonable out of pocket expenses.

M.E. "Hank" Durschlag became Interim CEO and Acting CFO on December 11, 2007. Mr. Durschlag's compensation of \$100,000 per annum did not change when he assumed the temporary positions, while he assisted the Company in finding a full-time CEO.

54

GRANTS OF PLAN BASED AWARDS TABLE AS OF DECEMBER 31, 2007

Name/Date	All other stock awards: number of shares of stock or units (#)	All other option awards: number of securities underlying options (#)	Exercise or Base price of Option awards	Grant value of option
Daniel J. Kelly January 1, 2007	-	400,000	\$ 2.25	\$
Robert S. Davidson May 4, 2007	-	495,000	\$ 1.36	\$
Matthew Burns May 4, 2007	-	495,000	\$ 1.36	\$
Gary Thomas January 1, 2007	-	50,000	\$ 2.25	\$
January 1, 2007	10,000	-	-	\$

Other required columns: estimated future payouts under non-equity incentive plan awards and estimated future payouts under equity incentive plan awards are omitted from the table as they are all zero.

NARRATIVE DISCLOSURE TO GRANTS OF PLAN BASED AWARDS TABLE

The award to Mr. Kelly was pursuant to his employment as President and Acting CEO. The awards to Mr. Davidson and Mr. Burns were replacements for options they had with InnoZen when it was acquired by the Company. The award to Mr. Thomas was granted to him upon initial employment.

OUTSTANDING EQUITY AWARDS AT FISCAL YEAR-END TABLE

Name	NUMBER OF SECURITIES underlying unexercised options (#)		Option exercise price (\$)	Option expiration date
	Exercisable	Unexercisable		

Edgar Filing: Healthsport, Inc. - Form 10-K

Daniel J. Kelly	100,000	-	\$ 1.10	September 12, 2009
Daniel J. Kelly	400,000	-	\$ 2.25	January 1, 2010
Robert S. Davidson	495,000	-	\$ 1.36	May 4, 2010
Matthew Burns	495,000	-	\$ 1.36	May 4, 2010
Gary Thomas	50,000	-	\$ 2.25	January 1, 2010

The columns for option awards - equity incentive plan awards: number of securities underlying unexercised unearned options and all four stock award columns are omitted from the table as these amounts were zero.

ADDITIONAL NARRATIVE DISCLOSURE

Mr. Kelly's option for 100,000 shares was granted while he was a consultant and before he became President and Acting CEO on January 1, 2007. Mr. Kelly's second option for 400,000 shares was granted when he became President and Acting CEO. Mr. Davidson and Mr. Burns received options on May 4, 2007 to replace options they had at InnoZen. The option for Mr. Thomas was granted upon his initial employment. Mr. Kusher and Mr. Durschlag did not have any options at December 31, 2007.

55

Options exercised and stock vested table, pension benefits table and nonqualified deferred compensation table and all omitted as there would have been no information to include.

COMPENSATION OF DIRECTORS TABLE - ADDITIONAL NARRATIVE DISCLOSURE

Directors did not receive any compensation for the meetings they attend in 2007. It is anticipated that a formal plan for compensation of Directors will be instituted during 2008 or 2009.

ITEM 12: SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS

The following table indicates all persons who, as of February 29, 2008, the most recent practicable date, are known by us to own beneficially more than 5% of any class of our outstanding voting securities. As of February 29, 2008, there were 42,898,397 shares of our common stock outstanding. Except as otherwise indicated below, to the best of our knowledge, each person named in the table has sole voting and investment power with respect to the securities beneficially owned by them as set forth opposite their name.

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS

TITLE OF CLASS	NAME AND ADDRESS OF BENEFICIAL OWNER	AMOUNT AND NATURE OF BENEFICIAL OWNER	% OF CLASS
-----	-----	-----	-----
Common	Zengen, Inc.	10,717,900	24.98%
Common	Tri-Strip Associates, LLC	2,393,962	5.58%

SECURITY OWNERSHIP OF MANAGEMENT

The following table indicates the beneficial ownership of the Company's voting

Edgar Filing: Healthsport, Inc. - Form 10-K

securities of all Directors of the Company and all Executive Officers who are not Directors of the Company, and all officers and directors as a group, as of February 29, 2008, the most recent practicable date. As of February 29, 2008, there were 42,898,397 shares of the Company's common stock outstanding. Except as otherwise indicated below, to the best of the Company's knowledge, each person named in the table has sole voting and investment power with respect to the securities beneficially owned by them as set forth opposite their name. All options are currently exercisable, unless otherwise indicated.

56

TITLE OF CLASS -----	NAME AND ADDRESS OF BENEFICIAL OWNER -----		AMOUNT AND NATURE OF BENEFICIAL OWNER -----	% OF CLASS -----
Common	Robert Kusher 15851 SW 41st Street, #700 Davie, FL 33331		-	0%
Common	Daniel J. Kelly 495 Commerce Drive, Suite 1 Amherst, New York	a	623,800	1.44%
Common	M.E. "Hank" Durschlag 5403 McChesney Dr Charlotte, NC 28269		575,000	1.34%
Common	Robert S. Davidson 6429 Independence Ave Woodland Hills, CA 91367	b,c	586,867	1.35%
Common	Matthew Burns 6429 Independence Ave Woodland Hills, CA 91367	b,c	497,000	1.15%
Common	Michael D. Pruitt 4201 Congress Street, Suite 145 Charlotte, NC 28277	d	125,000	**
Common	Gary Thomas 495 Commerce Drive, Suite 1 Amherst, New York	e	71,100	**
Common	All current officers and directors as a Group (6 persons)		2,478,767	5.90%

** Less than 1%.

a. Includes option granted in September 2006 for 100,000 shares exercisable at \$1.10 per share and option granted January 1, 2007 for 400,000 shares exercisable at \$2.25 per share.

b. Includes three-year option for 495,000 shares each exercisable at \$1.36 which was granted on May 4, 2007, as a part of the acquisition of InnoZen.

c. Does not include Mr. Davidson's approximate 6.15% interest in Zengen, Inc.'s 10,717,900 shares (approximately 659,000 shares); does not include Mr. Burns approximate 4.2% interest in Zengen,

Edgar Filing: Healthsport, Inc. - Form 10-K

Inc.'s 10,717,900 shares (approximately 454,000 shares).

- d. Includes 125,000 shares owned by Chanticleer Holdings, Inc. of which Mr. Pruitt is CEO and a director.
- e. Includes three-year option for 50,000 shares exercisable at \$2.25 which was granted on January 1, 2007.

57

EQUITY COMPENSATION PLANS			
	Approved by Security Holders	Not approved by Security Holders	Total
Number of securities to be issued upon exercise of outstanding options, warrants and rights	3,605,390	--	3,605,390
Weighted-average exercise price of outstanding options, warrants and rights	\$ 1.53	\$ --	\$ 1.53
Number of securities remaining available for future issuance under equity compensation plans (excluding securities above)	1,409,610	--	1,409,610

ITEM 13: CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE

2007 TRANSACTIONS

InnoZen repaid a loan to a principal shareholder and affiliate in the amount of \$108,285 after it was acquired by HealthSport.

2006 TRANSACTIONS

Effective August 20, 2006, we issued 65,000 shares of our common stock to a former CEO and transferred the stock of IMGI, including liabilities of \$295,840 to the former CEO. The liabilities included \$291,913 which the former CEO claimed was due to him and affiliates for costs advanced in the original formation of IMGI.

During the year ended December 31, 2006, we had three different part-time CEOs. In aggregate they were paid \$16,000 during the year.

58

ITEM 14: PRINCIPAL ACCOUNTANT FEES AND SERVICES

Audit Fees - The aggregate fees billed as of March 31, 2008 for professional services rendered by the Company's accountant was \$75,300 and \$31,900 for the audit of the Company's annual financial statements and quarterly reviews for the fiscal years ended December 31, 2007 and 2006, respectively.

Audit-Related Fees - None.

Edgar Filing: Healthsport, Inc. - Form 10-K

Tax Fees - None for 2007 or 2006.

All Other Fees - Other than the services described above, no other fees were billed for services rendered by the principal accountant during fiscal 2007 or fiscal 2006.

Audit Committee Policies and Procedures - The audit committee pre-approves audit and review services.

If greater than 50 percent, disclose the percentage of hours expended on the principal accountant's engagement to audit the registrant's financial statements for the most recent fiscal year that were attributed to work performed by persons other than the principal accountant's full-time, permanent employees - Not applicable.

59

PART IV

ITEM 15: EXHIBITS AND FINANCIAL STATEMENT SCHEDULES

(a) The following documents are filed as part of this report:

1. Financial Statements - The following consolidated financial statements of HealthSport, Inc. and Subsidiaries are contained in Item 8 of this Form 10-K:
 - o Report of Independent Registered Public Accountant
 - o Consolidated Balance Sheets at December 31, 2007 and 2006
 - o Consolidated Statements of Operations - For the years ended December 31, 2007 and 2006
 - o Consolidated Statements of Stockholders' Equity (Deficit) - For the years ended December 31, 2007 and 2006
 - o Statements of Cash Flows - For the years ended December 31, 2007 and 2006
 - o Notes to the Financial Statements
2. Financial Statement Schedules were omitted, as they are not required or are not applicable, or the required information is included in the Financial Statements.
3. Exhibits - The following exhibits are filed with this report or are incorporated herein by reference to a prior filing, in accordance with Rule 12b-32 under the Securities Exchange Act of 1934.

Exhibit -----	Description -----
31.1	Certification of the Chief Executive Officer pursuant to Rule 13a-14 of the Securities Exchange Act of 1934
31.2	Certification of the Chief Financial Officer pursuant to Rule 13a-14 of the Securities Exchange Act of 1934
32.1	Certification of the Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350
32.2	Certification of the Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350

60

SIGNATURES

Edgar Filing: Healthsport, Inc. - Form 10-K

In accordance with the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

HEALTHSPORT, INC.

April 14, 2008

/s/ Robert Kusher

Robert Kusher, CEO
(Principal executive officer)

April 14, 2008

/s/ M.E. "Hank" Durschlag

M.E. "Hank" Durschlag, Acting CFO
(Principal accounting officer)

In accordance with the Exchange Act, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

April 14, 2008

/s/ Robert Kusher

Robert Kusher, CEO

April 14, 2008

/s/ Robert S. Davidson

Robert S. Davidson, Director

April 14, 2008

/s/ M.E. "Hank" Durschlag

M.E. "Hank" Durschlag, Director

April 14, 2008

/s/ Daniel J. Kelly

Daniel J. Kelly, President and Director

April 14, 2008

/s/ Matthew Burns

Matthew Burns, Director and COO

April 14, 2008

/s/ Michael D. Pruitt

Michael D. Pruitt, Director